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Abstract 
TRPM2 is a calcium-permeable non-selective cation channel that acts as a mediator of 
cell death in response to oxidative stress. It has been shown that oxidative stress increases 
TRPM2 tyrosine phosphorylation and activation – an effect that is blocked by PP2, a 
non-specific inhibitor of Src family kinases.  However, the kinase and target TRPM2 
tyrosine residue(s) involved have not yet been identified.  Here, we investigated the 
potential regulation of TRPM2 by Fyn.  Intracellular application of recombinant Fyn 
potentiated TRPM2 currents in HEK293 cells expressing inducible TRPM2 (TRPM2-
HEK293 cells).  Further, a physical interaction between Fyn and TRPM2 was 
demonstrated by co-immunoprecipitation in TRPM2-HEK293 cells.  Additionally, 
tyrosine phosphorylation of TRPM2 was induced by Fyn in TRPM2-HEK293 cells, and 
the amount of phosphorylation detected was related to the activation state of Fyn.  We 
propose that by augmenting TRPM2 activity, Fyn kinase potentiates cellular calcium 
overload and facilitates cell death in response to oxidative stress.   
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INTRODUCTION 
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1.1 General introduction 
Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel that 
is permeable to calcium (Ca2+). TRPM2 is broadly expressed in the central nervous 
system (Nagamine et al., 1998), and expression of functional TRPM2 channels has been 
demonstrated in CA1 neurons of the hippocampus (Olah et al., 2009).  A physiological 
role for TRPM2 in neurons was recently identified; TRPM2 was shown to be required for 
N-methyl-D-aspartate receptor (NMDAR)-dependent long-term depression (Xie et al., 
2011).  Moreover, TRPM2 has been shown to function as a mediator of cell death in 
response to oxidative stress in neurons (Kaneko et al., 2006) and other cell types (Hara et 
al., 2002; Wehage et al., 2002).  As such, TRPM2 channel activation has been implicated 
in the pathogenesis of several oxidative stress-related neurodegenerative diseases. 
Mechanisms by which TRPM2 activation is regulated remain largely unexplored.  
However, it has been shown that tyrosine phosphorylation of TRPM2 is induced 
following oxidative stress (Zhang et al., 2007).  This phosphorylation coincides with an 
increase in TRPM2 channel activation (Zhang et al., 2007).  Further, this phosphorylation 
is reduced by protein tyrosine phosphatase-L1 (PTPL1), and PP2, a non-selective 
inhibitor of Src family kinases (SFK) (Zhang et al., 2007).  Fyn kinase is a ubiquitously 
expressed tyrosine kinase, which belongs to the SFK family (Salter & Kalia, 2004).  
Notably, like TRPM2, Fyn expression has been demonstrated in postsynaptic densities, 
its activation is augmented in response to oxidative stress and Fyn signaling has been 
shown to contribute to cell death (Ittner et al., 2010; Sanguinetti et al., 2003).  Further, 
preliminary evidence suggests that Fyn regulates TRPM2 activation through an NMDA 
receptor-independent mechanism (MacDonald/Jackson lab, unpublished).  This thesis 
will investigate the regulation of TRPM2 channels by Fyn kinase.  
 
1.2 Transient receptor potential melastatin 2 (TRPM2) 
Transient receptor potential melastatin 2 (TRPM2), previously designated TRPC7 and 
LTRPC2, is a non-selective cation channel, which is permeable to calcium (Ca2+).  
3 
 
 
TRPM2 belongs to the transient receptor potential (TRP) family of integral membrane 
ion channel proteins.  This protein family was named based on structural homology of its 
members to the TRP protein of Drosophila melanogaster (Hardie et al., 2001).  The 
Drosophila TRP protein, which was first isolated in 1989, was found to be essential for 
phototransduction (Montell & Rubin, 1989).  To date, 28 mammalian TRP proteins have 
been identified (Nilius & Owsianik, 2011).  Each TRP family member contains six 
transmembrane domains, forms a cation-permeable channel and has at least 20% 
sequence homology with other TRP family members (Montell, 2005; Clapham, 2003).  
However, within the TRP family, there is substantial diversity in expression patterns, 
activation mechanisms, regulatory mechanisms as well as cation permeability (Jiang et 
al., 2010; Sumoza-Toledo & Penner, 2011).  For example, TRP channels are variably 
activated by specific ligands, voltage, temperature and/or mechanical force (Holzer, 
2011).  Further, permeability and selectivity of TRP channels to Na+, K+, Ca2+ and Mg2+ 
vary substantially between family members (Sumoza-Toledo & Penner, 2011).  Although 
expression patterns and functions of TRP channels are highly diverse and vary for each 
family member, many TRP channels are expressed in the central nervous system and are 
involved in sensory processes (Montell, 2005).  Mammalian TRP proteins have been 
divided into six subfamilies based on sequence homology: canonical or classic (TRPC), 
vanilloid (TRPV), melastatin (TRPM), ankyrin (TRPA), polycystin (TRPP), mucolipin 
(TRPML) (Nilius & Owsianik, 2011).   
The TRPM subfamily, to which TRPM2 belongs, was named for melastatin (TRPM1), a 
tumor suppressor protein whose expression is inversely related to tumor size, 
aggressiveness and metastasis of human primary cutaneous melanomas (Duncan et al., 
1998).  The mammalian TRPM subfamily consists of eight members, denoted TRPM1–
TRPM8.  Six of the eight TRPM subfamily members can be further subdivided into pairs 
that display similar biophysical properties and high sequence homology (50-80%): 
TRPM1/3, TRPM4/5, TRPM6/7 (Nilius & Owsianik, 2011).  With respect to sequence 
homology, the remaining two TRPM proteins, TRPM2 and TRPM8, are less closely 
related to other TRPM subfamily members (Montell, 2005).  Like the TRP family as a 
whole, TRPM subfamily members exhibit substantial diversity in expression patterns, 
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activation mechanisms, regulatory mechanisms as well as cation permeability (Sumoza-
Toledo & Penner, 2011). 
The gene encoding human TRPM2 is located on chromosome 21q22.3, is 90 kb in length 
and contains 32 exons (Nagamine et al., 1998).  The human TRPM2 gene encodes an 
mRNA transcript of approximately 6.5 kb, which in turn encodes a 1503 amino acid 
(AA) protein with a molecular weight of approximately 170 kDa (Nagamine et al., 1998).  
Using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ 
hybridization, expression of TRPM2 mRNA was shown to be nearly ubiquitous (Fonfria 
et al., 2006; Jiang et al., 2010).  Notably, TRPM2 mRNA expression was highest in the 
brain and pituitary (Fonfria et al., 2006).  Further, functional expression of TRPM2 
protein has been demonstrated in several cell types, including neurons (Hill et al., 2006; 
Olah et al., 2009), microglia (Kraft et al., 2004), immunocytes (Sano et al., 2001), 
cardiomyocytes (Yang et al., 2006) and pancreatic β-islet cells (Togashi et al., 2006).  
Notably, functional TRPM2 channels have also been identified in hippocampal CA1 
pyramidal neurons (Olah et al., 2009).  Studies of TRPM2 channel function commonly 
use patch-clamp electrophysiology and/or Ca2+ imaging.  To confirm that TRPM2 
channels are specifically being studied, these techniques are often used in conjunction 
with established pharmacological agents (such as activators, antagonists and regulatory 
factors) and analysis of channel properties (such as reversal potential and current-voltage 
relationship).  Patch-clamp studies commonly involve recording adenosine diphosphate 
ribose (ADPR)-induced TRPM2 currents.  Alternatively, Ca2+ imaging typically involves 
using fluorescent Ca2+ indicators to monitor changes in intracellular Ca2+ concentration in 
response to oxidative stressors, such as hydrogen peroxide (H2O2).  Although TRPM2 has 
been predominantly characterized as a cell surface protein, a recent study showed that 
TRPM2 also functions as a lysosomal Ca2+-release channel in beta cells (Lange et al., 
2009).  Interestingly, in dendritic cells, TRPM2 functions as a lysosomal Ca2+-release 
channel, but not as a plasma membrane Ca2+-entry channel (Sumoza-Toledo et al., 2011).  
The physiological relevance and factors that determine cellular localization of TRPM2 
are not clearly defined at present. 
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1.3 Structural and biophysical properties of TRPM2 
TRPM2 channels are widely thought to consist of four subunits surrounding a central 
cation-conducting pore (Somoza-Toledo & Penner, 2011).  TRP channels belong to the 
same ion channel superfamily as voltage-gated K+, Na+ and Ca2+ channels, and 
consequently, they have similar membrane topology (Yu & Catterall, 2004).  Each 
subunit contains six transmembrane domains (S1-6), intracellular N- and C-terminal tails, 
and a pore-forming loop between S5 and S6 (Nagamine et al., 1998; Jiang et al., 2010).  
Figure 1 shows a schematic of TRPM2.  
The N-terminal tail of human TRPM2 is cytosolic and consists of 752 amino acids (AA 
1-752) (Maruyama et al., 2007).  The N-terminus contains four TRPM homology regions 
(MHR), which consist of amino acid stretches totaling approximately 700 AA in length 
that are highly conserved among members of the TRPM subfamily (Fleig & Penner, 
2004; Perraud et al., 2003).  The functional importance of these MHR regions has not yet 
been established (Fleig & Penner, 2004).  However, Perraud et al. (2003) have provided 
preliminary evidence that the MHR regions may contribute to tetrameric assembly and/or 
surface localization of TRPM2 channels.  Also within the N-terminal tail of TRPM2 is a 
calmodulin (CaM)-binding IQ-like motif (AA 406-416), which contributes to TRPM2 
channel facilitation and activation by intracellular Ca2+ (Tong et al., 2006) (see section 
1.7 for more details on Ca2+/CaM regulation of TRPM2 channels).   
The transmembrane portion of human TRPM2 is 294 amino acids in length (AA 753-
1046) and consists of six transmembrane domains interspersed with alternating 
extracellular and intracellular loops (Fig. 1; Jiang et al., 2010).  Loops connecting S2 and 
S3, as well as S4 and S5 are intracellular, and loops connecting S1 and S2, S3 and S4, as 
well as S5 and S6 are extracellular (Jiang et al., 2010).  The re-entrant extracellular pore-
loop connecting S5 and S6 (AA 958-1025) forms a central cation-permeating pore 
(Sumoza-Toledo & Penner, 2011).  Cysteine residues C996 and C1008 within the pore-
loop region have been identified as essential for TRPM2 channel function; point  
 Figure 1.1: Schematic images
Structural (A) and scaled linear (B) 
six transmembrane regions (TM1
terminus contains four conserved TRPM homology regions (MH
binding IQ-like motif.  The C
(CCR) and a NUDT9-H domain.  
A. 
B. 
 
 
 of human TRPM2. 
schematics of TRPM2.  TRPM2 channels consist of 
-6) as well as intracellular N- and C-termini.  The N
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mutations at these sites result in nonfunctional channels (Mei et al., 2006a).  Further, 
residues E960, Q981, D987 and E1022 are important determinants of divalent cation 
permeability (Xia et al., 2008).  The other transmembrane domain-connecting loops are 
short (3-56 AA), and their physiological functions are not well described at present. 
The C-terminal tail of human TRPM2 is cytosolic and consists of 457 amino acids (AA 
1047-1503) (Jiang et al., 2010).  Immediately distal to transmembrane segment S6, in the 
C-terminus of TRPM2, is a 23 amino acid TRP box motif (AA 1063-1085), which is a 
highly conserved region among members of the TRPM, TRPC and TRPV subfamilies 
(Clapham, 2003; Montell, 2005).  The function of the TRP box remains unclear at 
present.  Also within the C-terminal tail of TRPM2 is a coiled-coil region (CCR; AA 
1167-1201) (Mei et al., 2006b).  This CCR region is thought to contribute to the 
tetrameric assembly of TRPM2 subunits (Fleig & Penner, 2004).  Accordingly, deletion 
of the CCR resulted in a loss of TRPM2 subunit interaction and TRPM2 currents (Mei et 
al., 2006b).  Similarly, site-directed mutagenesis of specific residues within the CCR that 
have been implicated in protein-protein interactions also disrupted TRPM2 subunit 
interaction and TRPM2 currents (Mei et al., 2006b).  TRPM2 also contains a unique C-
terminal enzymatic domain called NUDT9-H (AA 1236-1503) (Jiang et al., 2010; 
Perraud et al., 2003).  TRPM2 channels are gated by binding of intracellular ADPR to 
this NUDT9-H domain (Perraud et al., 2001) (more details on TRPM2 activation 
mechanisms are provided in section 1.4).  The NUDT9-H domain is so named because it 
displays substantial sequence homology (39%) to the mitochondrial ADPR 
pyrophosphatase NUDT9, an enzyme that catalyzes the hydrolysis of ADPR to adenosine 
monophosphate (AMP) and ribose-5-phosphate (Shen et al., 2003).  TRPM2 has been 
called a ‘chanzyme’ because it functions as both an ion channel and an enzyme (Perraud 
et al., 2003).  Notably, when expressed in E. coli, the ADPR hydrolase activity of the 
NUDT9-H was over 100 times lower than NUDT9 (Perraud et al., 2001; Shen et al., 
2003).  However, both NUDT9-H and NUDT9 displayed identical affinities for ADPR 
and substrate specificity for ADPR compared to other nucleoside diphosphate derivatives 
tested (Perraud et al., 2001).  Amino acids substitutions at residues 1405-1406 of TRPM2 
have been implicated as critical for the reduction in activity of NUDT9-H relative to 
NUDT9 (Kuhn & Luckhoff, 2004).  Interestingly, mutations I1405E/L1406F within 
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NUDT9-H fully restored the enzymatic activity of this region relative to NUDT9, but 
abolished ADPR-induced TRPM2 activation (Kuhn & Luckhoff, 2004).  Perraud et al. 
(2005) suggested that the NUDT9-H domain may be an evolutionary adaptation of the 
ADPR-binding region of the NUDT9 enzyme into an ADPR-dependent gating 
mechanism for TRPM2.  Although a specific role for the enzymatic activity of NUDT9-
H, beyond gating of TRPM2, has not yet been identified, the possibility that this 
enzymatic activity may serve some physiological function should not be excluded.  In 
addition to its role in TRPM2 channel gating, the NUDT9-H domain has also been 
implicated in TRPM2 channel assembly and surface trafficking (Perraud et al., 2003). 
TRPM2 is a non-selective cation channel that displays significant permeability to Na+, 
K+, Ca2+ and Mg2+ (Xia et al., 2008).  The relative permeabilities of these cations are 1 
Na+:1.1 K+:0.9 Ca2+:0.5 Mg2+ (Xia et al., 2008).  Thus, the inward current mediated by 
TRPM2 is primarily attributable to Na+ movement, but the channel is also significantly 
permeant to Ca2+.  The single-channel conductance of TRPM2 is approximately 50-80 
pS, with a mean channel open time on the order of several seconds (Jiang et al., 2010; 
Perraud et al., 2001).  Open TRPM2 channels display a linear current-voltage (I-V) 
relationship, which implies that TRPM2 channel gating is not voltage-dependent (Perraud 
et al., 2001; Sano et al., 2001).  Further, TRPM2 has a reversal potential of approximately 
0 mV, which is characteristic of non-selective cation channels (Perraud et al., 2001; Sano 
et al., 2001).   
Several identified TRPM2 splice variants have provided insight into how TRPM2 
structure relates to channel function.  TRPM2-S (848 AA) is a splice variant that contains 
a premature stop codon, resulting in a non-functional truncated protein that contains only 
the N-terminal tail and the first two transmembrane domains (Zhang et al., 2003).  
TRPM2-SSF (1289 AA) is a striatum shorter form of TRPM2 with a deletion of AA 1-
214 (Uemura et al., 2005).  TRPM2-SSF displays substantially less channel activity than 
full-length TRPM2 (Uemura et al., 2005).  TRPM2-∆N (1483 AA) is a variant with 
deletion of AA 538-557, TRPM2-∆C (1469 AA) has deletions of AA 1292-1325, and 
TRPM2-∆N∆C has deletions of AA 538-557 and AA 1292-1325 (Wehage et al., 2002).  
Currents were not significantly stimulated by ADPR or H2O2 in TRPM2-∆N or TRPM2-
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∆N∆C (Wehage et al., 2002).  Interestingly, H2O2, but not ADPR, significantly 
stimulated currents in TRPM2-∆C, which contains a partially disrupted ADPR-binding 
NUDT9-H domain (Wehage et al., 2002) (more details on TRPM2 activation 
mechanisms are provided in section 1.4). 
 
1.4 Oxidative stress and TRPM2 activation 
Oxidative stress refers to an imbalance in cellular redox state, which is marked by the 
generation of reactive oxygen species (ROS) (Miller & Zhang, 2011).  ROS, such as 
H2O2, are highly reactive and can induce cellular damage by oxidation of DNA and 
proteins as well as lipid peroxidation (Miller & Zhang, 2011).  Oxidative stress has been 
widely implicated as a causative factor in the pathogenesis of several diseases, including 
cancer (Halliwell, 2007), stroke (Allen & Bayraktutan, 2009), Alzheimer’s disease 
(Saltana & Butterfield, 2010), atherosclerosis (Vogiatzi et al., 2009), and many others.  
However, the molecular signaling pathways underlying oxidative damage are complex.  
A common event following oxidative stress is an elevation in cytosolic free Ca2+ 
concentrations ([Ca2+]i) (Jiang et al., 2010).  Increased [Ca2+]i may result from activation 
of Ca2+-permeable ion channels on the plasma membrane or release from intracellular 
Ca2+ stores, such as the endoplasmic reticulum (ER) (Clapham, 2007).  Subsequently, 
intracellular Ca2+ exerts pleiotropic effects within cells through diverse signaling 
pathways (Berridge et al., 2000; Clapham, 2007).  For example, Ca2+ signaling has been 
implicated in modulating cellular excitability and mediating cell death (Clapham, 2007).  
TRPM2 channels provide a means by which [Ca2+]i is increased in response to oxidative 
stress.   
As described in section 1.3, TRPM2 channels are activated by binding of intracellular 
agonist ADPR to the NUDT9-H domain of TRPM2 (Perraud et al., 2001).  ADPR is the 
most potent activator of TRPM2, with half-maximal effective concentrations (EC50) for 
TRPM2 activation by ADPR variably reported in the range of 10-90 µM (Jiang et al., 
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2010), which is comparable to reported endogenous intracellular ADPR levels of 5-75 
µM (Gasser & Guse, 2005; Heiner et al., 2006). 
Nicotinamide adenine dinucleotide (NAD+) has also been shown to activate TRPM2 
channels (Sano et al., 2001).  NAD+ is a less potent TRPM2 activator than ADPR and has 
an EC50 of approximately 1-1.8 mM (Jiang et al., 2010).  Although some sources have 
suggested that NAD+ directly activates TRPM2 (Hara et al., 2002; Sano et al., 2001), 
others have suggested that NAD+ is first converted to ADPR, which in turn gates TRPM2 
(Perraud et al., 2005; Wehage et al., 2002).  NAD+ can be converted to ADPR by 
sequential enzymatic actions of polyADPR-polymerase (PARP), which converts NAD+ 
into polyADPR, and polyADPR-glycohydrolase (PARG), which breaks down polyADPR 
into monomeric ADPR (Blenn et al., 2011).  Alternatively, NAD+ can be directly 
hydrolyzed by NAD+ glycohydrolase (NADase) enzymes into ADPR (Knowles et al., 
2013).  Thus, NAD+ may activate TRPM2 by a direct, ADPR-independent mechanism or 
through the production of ADPR.  TRPM2 activation has also been demonstrated in 
response to several other molecules that are metabolically related to ADPR, such as 
cyclic ADPR (cADPR; EC50 = 0.7 mM), and nicotinic acid-adenine dinucleotide 
phosphate (NAADP; EC50 = 0.73 mM) (Jiang et al., 2010).  The mechanisms by which 
such agents induce TRPM2 activation is unclear at present, but it has been proposed that 
they may bind to an alternate site on TRPM2 or be converted metabolically to ADPR, 
which in turn activates TRPM2 (Beck et al., 2006). 
TRPM2 channel activation has also been demonstrated in response to ROS, such as H2O2 
(Hara et al., 2002; Wehage et al., 2002).  Activation of TRPM2 channels by H2O2 has 
been proposed to occur through ADPR-independent and ADPR-dependent mechanisms.  
Wehage et al. (2002) demonstrated that H2O2 significantly stimulated currents in the 
ADPR-insensitive TRPM2-∆C splice variant.  This finding supports the idea that H2O2 
induces TRPM2 activation through an ADPR-independent mechanism.  However, the 
mechanism underlying ADPR-independent TRPM2 activation is not clearly defined at 
present.  On the other hand, an ADPR-dependent mechanism has been proposed: H2O2 
stimulates activation of PARP/PARG and NADase enzymes, which results in conversion 
of NAD+ to ADPR, which in turn activates TRPM2 (Takahashi et al., 2011). 
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Ca2+ ions also play an important role in TRPM2 activation.  It is widely accepted that 
both intracellular and extracellular Ca2+ are critical regulators of TRPM2 activation by 
ADPR (McHugh et al., 2003; Tong et al., 2006) (more details on TRPM2 regulation by 
Ca2+ are provided in section 1.7).  Other studies have shown that intracellular Ca2+ can 
actually gate TRPM2 channels through an ADPR-independent mechanism (McHugh et 
al., 2003; Du et al., 2009a).  Du et al. (2009a) showed that intracellular Ca2+ can activate 
currents in TRPM2 mutants with disrupted ADPR binding motifs as well as the ADPR-
insensitive splice variants TRPM2-∆N, TRPM2-∆C and TRPM2-∆N∆C.  Notably, 
activation of TRPM2 by Ca2+ alone (EC50 = 16.9 µM) was greatly facilitated by the 
presence of 10 µM ADPR (EC50 = 0.49 µM) (Du et al., 2009a).  This suggests that 
TRPM2 is activated synergistically by both ADPR and Ca2+.  It follows that after 
oxidative stress, ADPR levels increase, TRPM2 channels are activated, and local [Ca2+]i 
increases, which in turn potentiates TRPM2 activation via a positive feedback loop 
(McHugh et al., 2003).  Because TRPM2 mediates susceptibility to cell death in response 
to oxidative stress, it has been implicated in the pathogenesis of several oxidative stress-
related diseases (more details on TRPM2 in central nervous system (CNS) disease are 
provided in section 1.6). 
 
1.5 Physiological roles of TRPM2 
A variety of physiological roles have been ascribed to TRPM2.  For example, TRPM2 
activation has been implicated in insulin release from β-islet cells of the pancreas 
(Togashi et al., 2006).  Uchida et al. (2011) showed that basal blood glucose levels were 
higher in TRPM2 knockout (TRPM2-KO) mice compared to wild-type (TRPM2-WT) 
mice.  Further, in isolated β-cells, glucose-evoked cellular Ca2+ influx and insulin 
secretion were reduced in TRPM2-KO compared to TRPM2-WT (Uchida et al., 2011).  
TRPM2 has also been shown to contribute to cytokine production in immune cells 
(Yamamoto et al., 2008).  For example, Yamamoto et al. (2008) showed that H2O2-
induced production of the chemokine CXCL2 in murine monocytes is dependent on 
TRPM2 Ca2+ influx; CXCL2 production is impaired in TRPM2-KO mice.  Additionally, 
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TRPM2 was shown to be essential for lipopolysaccharide-induced production of 
cytokines IL-6, IL-8, IL-10 and TNF-α (Wehrhahn et al., 2010).  TRPM2 has also been 
implicated as a regulator of dendritic cell chemotaxis in response to cytokines; TRPM2-
deficient dendritic cells display impaired cytokine-induced chemotaxis (Sumoza-Toledo 
et al., 2011).  Further, TRPM2 has also been shown to mediate H2O2-induced increases in 
vascular endothelial permeability (Hequet et al., 2008).  Although TRPM2 expression is 
most abundant in the CNS (Sumoza-Toledo & Penner, 2011) and several physiological 
roles of TRPM2 in peripheral tissues have been identified, the physiological functions of 
TRPM2 in the CNS were until recently unknown.  However, Xie et al. (2011) showed 
that TRPM2 plays a role in hippocampal synaptic plasticity.  Specifically, loss of TRPM2 
expression in TRPM2-KO mice impairs NMDAR-dependent long-term depression (Xie 
et al., 2011).  One of the best-described roles of TRPM2 is that its activation confers 
susceptibility to cell death in response to oxidative stress (Hara et al., 2002; Wehage et 
al., 2002).  The contribution of TRPM2 to cell death is described in detail in section 1.4.  
However, when dysregulated, this function of TRPM2 may contribute to various 
pathologies. 
 
1.6 TRPM2 channels in CNS disease 
Several neurological pathologies are characterized by dysregulation of Ca2+ homeostasis 
in response to oxidative stress (Zundorf & Reiser, 2011).  TRPM2 activation has been 
shown to mediate cellular Ca2+ influx and susceptibility to cell death in response to 
oxidative stress (Hara et al., 2002; Wehage et al., 2002).  As such, excessive TRPM2 
activation may contribute to the pathogenesis of several oxidative stress-related 
pathologies (Jiang et al., 2010).  Details on activation of TRPM2 channels in response to 
oxidative stress are provided in section 1.4.  The expression of TRPM2 in a variety of 
tissues as well as its role as a mediator of cell death makes it an attractive therapeutic 
target for several diseases.   
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TRPM2 has been linked to neurological disorders through identification of genetic 
variants.  For example, TRPM2 has been linked to Western Pacific amyotrophic lateral 
sclerosis (ALS) and Parkinsonism-dementia (PD) (Hermosura & Garruto, 2007).  A 
single nucleotide polymporphism, resulting in substitution of proline 1018 to leucine 
(P1018L), was found to be closely associated with a subset of Western Pacific ALS and 
PD (Hermosura et al., 2008).  This mutation results in faster inactivation of TRPM2-
P1018 relative to TRPM2-WT (Hermosura et al., 2008).  Similarly, single nucleotide 
polymorphisms, such as aspartic acid 543 to glutamic acid (D543E), have been linked to 
bipolar disorder (McQuillin et al., 2006).  However, in each case, the functional relevance 
of genetic variants in TRPM2 to disease pathology remains unclear at present. 
TRPM2 activation has been implicated in the pathogenesis of Alzheimer’s disease (AD).  
The amyloid hypothesis, a prominent theory of AD pathogenesis, proposes that that β-
amyloid (Aβ), a peptide that accumulates in the brains of AD patients, is the neurotoxic 
agent that drives AD pathogenesis (Hardy and Selkoe, 2002).  A recent study showed that 
activation of TRPM2 channels contributes to Aβ-induced death in rat primary striatal 
cultures (Fonfria et al., 2005).  Transfection of cells with the TRPM2-S splice variant, 
which inhibits TRPM2 in a dominant negative fashion, blocked Aβ-induced increases in 
[Ca2+]i and cell death (Fonfria et al., 2005).  Further, mRNA knockdown of TRPM2 
reduced Aβ toxicity (Fonfria et al., 2005).  Notably, degeneration of striatal neurons is 
not a major characteristic of AD; hippocampal neurons are more important in this respect.   
Whether TRPM2 is involved in the degeneration of hippocampal pyramidal neurons 
remains an open question.  Further, the molecular mechanism by which TRPM2 may 
contribute to Aβ toxicity in AD has not yet been identified. 
Recent evidence also suggests that TRPM2 may play a role in stroke pathology.  Fonfria 
et al. (2006) demonstrated that in the rat transient middle cerebral artery occlusion model 
of stroke, TRPM2 mRNA expression is elevated 1 and 4 weeks after ischemic injury.  
Further, during acute ischemia in vivo or oxygen glucose deprivation in vitro, a TRP-like 
channel is activated, resulting in increased [Ca2+]i (Lipski et al., 2006).  While this 
evidence doesn’t conclusively implicate TRPM2 as a pathogenic factor in stroke, it does 
provide preliminary support for this notion. 
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1.7 TRPM2 regulation mechanisms 
As previously described, a number of pharmacological agents have been shown to 
regulate TRPM2 activation.  Several inhibitors of TRPM2 activation have been 
identified.  For example, AMP, an enzymatic breakdown product of ADPR by NUDT9 
and NUDT9-H, can antagonize TRPM2 activation (half-maximal inhibitory 
concentration [IC50] = 10-70 µM) by ADPR, NAD+, cADPR and NAADP (Beck et al., 
2006; Kolisek et al., 2005; Lange et al., 2008).  Mechanistically, AMP is widely thought 
to inhibit TRPM2 by competitively binding to the ADPR binding site in the NUDT9-H 
domain of TRPM2 (Sumoza-Toledo & Penner, 2011).  Alternatively, 8-Br-cADPR 
inhibits TRPM2 activation by cADPR and H2O2, but can synergize TRPM2 activation by 
ADPR (Kolisek et al., 2005).  Other non-specific TRPM2 antagonists include 
clotrimazole, flufenamic acid (FFA) and N-(p-amylcinnamoyl)anthranilic acid (ACA) 
(Kraft et al., 2006).  However, no specific pharmacological inhibitors have been 
identified for TRPM2 to date. 
As described briefly in sections 1.3 and 1.4, Ca2+ is an important regulator of TRPM2 
function.  Importantly, both intracellular and extracellular Ca2+ influence channel 
activation.  In the absence of both extracellular and intracellular Ca2+, ADPR is not 
sufficient to induce TRPM2 currents (Starkus et al., 2007).  Further, in the absence of 
intracellular Ca2+, ADPR alone could not activate TRPM2 (Perraud et al., 2001).   In the 
absence of extracellular Ca2+, ADPR induced TRPM2 activation when [Ca2+]i was at 
least 30 nM (Starkus et al., 2007).  TRPM2 activation by ADPR is markedly facilitated 
by intracellular Ca2+ (Perraud et al., 2001; Tong et al., 2006).  Mechanistically, 
intracellular Ca2+ binds to the small Ca2+-binding protein CaM, which in turn binds the 
IQ-like motif in the N-terminal tail of TRPM2 and facilitates channel activation 
(Sumoza-Toledo & Penner, 2011).  Notably, Ca2+/CaM binding to the IQ-like motif was 
shown to be essential for TRPM2 activation (Tong et al., 2006).  TRPM2 channel 
inactivation has been observed for [Ca2+]i lower than 100 nM (Starkus et al., 2007).  
Some studies have shown that intracellular Ca2+ can actually gate TRPM2 channels 
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through an ADPR-independent mechanism (McHugh et al., 2003; Du et al., 2009a) (more 
details on gating of TRPM2 by Ca2+ are provided in section 1.3).  Notably, although Ca2+ 
may gate TRPM2 independently of ADPR, it has also been shown that elevated [Ca2+]i 
also increases the sensitivity of TRPM2 for ADPR (Starkus et al., 2007).  Extracellular 
Ca2+ is also an important modulator of TRPM2 function (Csanady & Torocsik, 2009; 
Starkus et al., 2007).  Extracellular Ca2+ that enters cells through TRPM2 during channel 
activation can facilitate further channel activation through a positive feedback mechanism 
(Tong et al., 2006).  Using fast and slow intracellular Ca2+ buffering and varying resting 
[Ca2+]i, McHugh et al., (2003) demonstrated that TRPM2 activation was ultimately 
regulated by intracellular Ca2+.  By extension, extracellular Ca2+ was proposed to 
modulate TRPM2 function by entering cells and acting on a TRPM2-associated Ca2+ 
sensor (McHugh et al., 2003).  
TRPM2 channels are also regulated by acidic pH.  Both intracellular and extracellular 
protons were shown to block TRPM2 channels (IC50: pH 5.3 for external, pH 6.7 for 
internal) (Du et al., 2009b).  However, the mechanism underlying TRPM2 regulation by 
acidification is unclear at present (Du et al., 2009b; Yang et al., 2010).  Additionally, 
Togashi et al. (2006) demonstrated that TRPM2 gating exhibits temperature-dependence.  
Notably, the temperature sensitivity of TRPM2 is augmented by the presence of 
intracellular ADPR, NAD and cADPR, which suggests that temperature may facilitate 
TRPM2 activation by these agents (Togashi et al., 2006). 
 
1.8 TRPM2 regulation by tyrosine phosphorylation 
It was recently reported that tyrosine phosphorylation of TRPM2 increases channel 
activation (Zhang et al., 2007).  In HEK293 cells expressing TRPM2, H2O2 treatment 
increased tyrosine phosphorylation of TRPM2, [Ca2+]i and apoptotic cell death—effects 
that were mitigated by the tyrosine phosphatase PTPL1 (Zhang et al., 2007).  This 
suggests that a tyrosine phosphorylation event is responsible for regulating TRPM2 
activation and modulating susceptibility to cell death.  Notably, this study used Ca2+ 
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imaging to study TRPM2 function.  However, this technique does not specifically assess 
TRPM2 function, as rises in [Ca2+]i could be attributable to release from intracellular 
stores or other Ca2+-permeable membrane channels.  Further, the kinase responsible for 
this phosphorylation and the tyrosine residue(s) phosphorylated remain unknown.  
PTPL1 was also shown to physically interact with TRPM2 by immunoprecipitation and 
glutathione-S-transferase pull-down assays (Zhang et al., 2007).  Notably, PTPL1 has 
been implicated in cell survival and tumorigenesis (Freiss & Chalbos, 2011).  Zhang et al. 
(2007) also showed that treatment of cells with genistein, a non-specific tyrosine kinase 
inhibitor, reduced H2O2-induced tyrosine phosphorylation of TRPM2, Ca2+ influx and 
cell death (Zhang et al., 2007).  Further, treatment of cells with PP2, an inhibitor of Src 
family tyrosine kinases (SFKs), similarly reduced H2O2-induced tyrosine phosphorylation 
of TRPM2, Ca2+ influx and cell death.  However, PP2 is a non-specific inhibitor of SFKs, 
and the specific SFK member involved has not yet been identified.  Taken together, these 
findings support the idea that tyrosine phosphorylation of TRPM2 is important for 
regulation of channel activation.  Zhang et al. (2007) proposed three mechanisms by 
which TRPM2 phosphorylation may affect channel activation: (1) phosphorylation of the 
NUDT9-H domain, which may affect ADPR binding, (2) phosphorylation of CaM 
binding sites, which may affect Ca2+/CaM regulation, or (3) phosphorylation of sites 
critical for pore function, which may affect channel opening or permeability.  Modulation 
of TRPM2 tyrosine phosphorylation, and consequently channel activation, may be a 
pathway by which susceptibility to cell death is modulated.   
 
1.9 Fyn kinase 
Fyn kinase is a cytosolic protein that phosphorylates substrate proteins on tyrosine 
residues.  Fyn is a member of the Src family of non-receptor protein tyrosine kinases 
(SFK).  This protein family was named based on structural homology of its members to 
Src, the prototypical member of the family, which was first identified in Rous sarcoma 
virus (Scales et al., 2011).  The SFK family consists of eight members, which are 
subdivided into subfamilies based on amino acid sequence homology: Src-related (Src, 
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Fyn, Yes, Fgr) and Lyn-related (Lyn, Lck, Hck, Blk) (Ingley, 2008).  There are also three 
Src-related kinases (Brk, Frk, Srm), which have a similar domain structure to Src kinases 
(Ingley, 2008).  There is a high degree of amino acid sequence conservation among SFK 
members.  Outside of an N-terminal domain whose sequence is almost completely unique 
to each member, SFKs share approximately 70% amino acid sequence identity (Hunter, 
1997).  However, within the SFK family, there is substantial diversity in expression 
patterns, regulatory mechanisms and implicated signaling pathways (Engen et al., 2008).  
Notably, five SFK members are expressed in the mammalian CNS: Src, Fyn, Yes, Lck 
and Lyn (Salter & Kalia, 2004). 
The gene encoding human Fyn is located on chromosome 6q21, is 213 kb in length and 
contains 14 exons (Popescu et al., 1987).  To date, three major alternatively spliced 
isoforms of Fyn have been identified (Cooke & Perlmutter, 1989; Goldsmith et al., 2002).  
Notably, only one of the isoforms (Fyn-B) is highly expressed in the central nervous 
system (Cooke & Perlmutter, 1989; Long et al., 2011).  For isoform Fyn-B, the Fyn gene 
encodes an mRNA transcript of approximately 3.6 kb, which in turn encodes a 537 AA 
protein with a molecular weight of approximately 59 kDa (Resh, 1998).   
Structurally, Fyn shares a conserved domain structure with the other SFK members.  This 
structure consists of (from N- to C-terminus): a Src homology 4 (SH4) domain, unique 
domain (UD), SH3 domain, SH2 domain, linker region, catalytic domain and regulatory 
domain (Salter & Kalia, 2004).  The N-terminal SH4 domain contains sites for lipid 
modifications, such as myristoylation, which are important for anchoring Fyn to the 
cytosolic face of membranes (Rawat & Nagaraj, 2010).  The UD is an N-terminal region 
whose size and sequence are highly variable between SFK members (Pérez et al., 2009).  
It follows that the UD may play a role in determining specificity of SFKs, such as 
substrate selectivity, protein-protein interactions and/or regulation of activity.  For 
example, UDs of some SFKs have been shown to mediate protein-protein interactions.  
Gingritch et al. (2004) showed that Src interacts with NADH dehydrogenase subunit 2 
(ND2), which in turn interacts with NMDAR.  Anchoring of Src to the NMDAR complex 
through Src’s UD is critical for regulation of NMDAR activity and, resultantly, synaptic 
transmission and plasticity (Gingritch et al., 2004).  However, the function of Fyn’s UD 
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remains unknown.  The SH3 domain is a highly conserved region that mediates 
interactions with other proteins (Hauck et al., 2001).  Specifically, the SH3 domain binds 
proline-rich sequences containing a PxxP motif (where ‘x’ represents any amino acid) 
(Hauck et al., 2001).  Similarly, the SH2 domain is a highly conserved region that also 
mediates protein-protein interactions (Nachman et al., 2010).  SH2 binds to sequences 
containing phosphorylated tyrosine residues (Nachman et al., 2010).  The linker region 
participates in intramolecular interactions and regulates Fyn activation (Pérez et al., 
2013). The catalytic domain transfers a phosphate group from adenosine triphosphate 
(ATP) to specific tyrosine residue(s) on substrate proteins (Thomas & Brugge, 1997).  
The C-terminal regulatory domain is a short region involved in regulating kinase activity 
(Kim & Lee, 2005). 
Activation of Fyn is primarily regulated by phosphorylation events and intramolecular 
interactions.  Autophosphorylation of a tyrosine residue (Y420) within the catalytic 
domain induces Fyn activation (Thomas & Brugge, 1997).  Importantly, phosphorylation 
of Y420 is the primary regulator of Fyn activation and is essential for Fyn activation 
(Cheng et al., 1991).  In addition to self-phosphorylation, the phosphorylation state of 
Fyn-Y420 is regulated by kinases, such as ErbB4 (or an ErbB4-activated tyrosine kinase) 
(Bjarnadottir et al., 2007) and phosphatases, such as striatal enriched phosphatase 61 
(STEP61) (Nguyen et al., 2002).  The C-terminal regulatory domain contains a tyrosine 
residue (Y531) that, when phosphorylated, interacts with the SH2 domain and stabilizes 
an inactive conformation (Kim & Lee, 2005).  Phosphorylation of Fyn-Y531 is regulated 
by kinases, such as Csk (Colognato et al., 2004) , and phosphatases, such as protein 
tyrosine phosphatase α (PTPα) (Gibb et al., 2011).  Further, phosphorylation of an N-
terminal serine residue (S21) by protein kinase A (PKA) is involved in regulating Fyn 
activity (Yeo et al., 2011).  Site-directed mutagenesis of this serine to alanine (S21A) 
ablates phosphorylation at this site and decreases Fyn activity (Yeo et al., 2011).  
Notably, the linker region is a short sequence that contains an SH3 substrate motif (PxxP) 
that stabilizes an inactive conformation when bound to the SH3 domain (Pérez et al., 
2013).  Fyn activity is also increased by ROS such as H2O2 (Abe and Berk, 1999; 
Sanguinetti et al., 2003).   
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1.10 TRPM2, Fyn and NMDA receptor signaling 
N-methyl-D-aspartate (NMDA) receptor (NMDAR) is a glutamate-gated ionotropic 
receptor.  Like TRPM2, NMDAR is a non-selective cation channel, which is significantly 
permeable to Na+, K+ and Ca2+ (Sakurada et al., 1993).  Notably, NMDARs display 
voltage-dependent blockage by Mg2+ at resting membrane potential (Sakurada et al., 
1993).  Under normal physiological conditions, NMDARs play a role in synaptic 
transmission at glutamatergic synapses.  At these synapses, glutamate binds to α-amino-
3-hyroxy-5-methyl-4-isoazoleproprionic acid (AMPA) receptors (AMPARs), activating 
them and causing depolarization of the postsynaptic cell.  Such depolarization is 
sufficient to relieve the voltage-dependent Mg2+ block of NMDARs.  Subsequently, 
binding of co-agonists glutamate and glycine induces NMDAR activation (Kew & Kemp, 
2005).  Such NMDAR activation induces an acute rise in [Ca2+]i.  Cellular influx of Ca2+ 
through NMDARs has been implicated in a number of physiological processes, such as 
synaptic plasticity (Liu et al., 2004).  However, under pathological conditions, excessive 
Ca2+ influx through NMDARs has been shown to contribute to neuronal death (Choi, 
1992). 
Co-activation of TRPM2 and NMDAR may cause excessive Ca2+ influx and as a result 
promote neuronal death. As described in section 1.7, activation of TRPM2 is dependent 
on extracellular and intracellular Ca2+ (McHugh et al., 2003). Intracellular Ca2+ has been 
shown to facilitate ADPR-mediated TRPM2 activation (McHugh et al., 2003). 
Interestingly, intracellular Ca2+ has also been shown to gate TRPM2 activation by an 
ADPR-independent mechanism (Du et al., 2009a).  Notably, ADPR alone was 
insufficient to gate TRPM2 channels in CA1 pyramidal neurons; Olah et al. (2009) 
observed that an additional influx of Ca2+ through NMDARs was necessary to induce 
TRPM2 activation.  Further, clotrimazole, a TRPM2 antagonist, was shown to reduce 
glutamate-induced Ca2+ overload and neuronal death in rat hippocampal pyramidal 
neurons (Isaev et al., 2002). Thus, there appears to be a functional connection between 
TRPM2 and NMDAR. 
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SFKs, including Fyn, have also been shown to regulate NMDAR function by tyrosine 
phosphorylation.  For example, Src has been shown to phosphorylate NMDARs, and 
intracellular application of recombinant Src was shown to increase NMDAR currents 
(Wang & Salter, 1994).  Further, phosphorylation of NMDAR by Fyn has been 
demonstrated (Salter and Kalia, 2004). This phosphorylation has been linked with 
increased NMDAR current and pathological levels of intracellular Ca2+ (Ittner et al., 
2010).  Notably, regulation of NMDARs by SFKs is subtype-specific.  Specifically, Src 
selectively phosphorylates and regulates GluN2A subunit-containing NMDARs, whereas 
Fyn selectively phosphorylates and regulates GluN2B subunit-containing NMDARs 
(Yang et al., 2011).  GluN2B subunit-containing NMDARs, whose activities are 
potentiated by Fyn, have been implicated in neuronal apoptosis (Hardingham et al., 2002; 
Yang et al., 2011).  It follows that TRPM2, Fyn and NMDARs may contribute to Ca2+ 
dysregulation and cell death in neurons. 
 
1.11 Rationale and hypothesis 
As described in section 1.8, H2O2-induced tyrosine phosphorylation of TRPM2, which 
coincides with increased channel activation, was reduced by PP2, a non-selective SFK 
inhibitor (Zhang et al., 2007).  This suggests that TRPM2 activation is regulated by a 
SFK, which has not yet been identified.  TRPM2 currents can be activated in cultured 
hippocampal CA1 neurons by repeated applications of NMDA in the absence of 
exogenous ADPR (MacDonald lab, unpublished).  Interestingly, with intracellular 
applications of recombinant Fyn, repeated NMDA applications resulted in increased 
TRPM2 currents over time―an effect that was abolished by inhibition of Fyn signaling 
(MacDonald/Jackson lab, unpublished).  This potentiation of TRPM2 current could be 
due to an increase in NMDAR currents or an enhancement of TRPM2 activation or both.  
Taken together, these findings suggest that Fyn may be a SFK involved in regulation of 
TRPM2 activation.  Thus, this thesis will investigate the potential regulation of TRPM2 
channels by Fyn kinase. 
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We hypothesize that Fyn kinase phosphorylates TRPM2 channels and enhances their 
function, resulting in larger TRPM2 currents.  Our specific objectives are (1) to 
demonstrate that Fyn regulates TRPM2 currents, (2) to determine whether Fyn induces 
tyrosine phosphorylation of TRPM2, and (3) to characterize the potential physical 
interaction between Fyn and TRPM2. 
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Section 2 
 
MATERIALS AND METHODS 
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2.1 Cell culture 
HEK293 cells stably expressing inducible FLAG-epitope-tagged TRPM2 (TRPM2-
HEK293 cells) were generously provided by Dr. A.M. Sharenberg (University of 
Washington, and Children’s Hospital and Medical Center, Seattle, WA).  The T-RExTM 
System (Invitrogen, CA) used to generate this cell line is a tetracycline-regulated 
mammalian expression system.  Transcriptional activation of FLAG-TRPM2 can be 
induced by binding of tetracycline or doxycycline to a Tet repressor controlling FLAG-
TRPM2 expression.  HEK293T cells were generously provided by Dr. H.H.M.Van Tol 
(University of Toronto, and Centre for Addiction and Mental Health, Toronto, ON).  
TRPM2-HEK293 cells and HEK293T cells were cultured at 37°C and 5% CO2 in 100 
mm culture dishes containing 10 mL Dulbecco’s modified Eagle’s medium  (DMEM; 
Sigma-Aldrich, MO) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich).  
Cells were split every 3-4 days to a maximum of 35 passages.   
 
2.2 Whole-cell voltage-clamp electrophysiology 
For electrophysiological recordings, TRPM2-HEK293 cells were plated on 35 mm 
culture dishes 1-2 days prior to recording.  TRPM2 expression was induced by 
administration of doxycycline (1.0 µg/mL) 18-24 hours prior to electrophysiological 
recordings.  Whole-cell voltage-clamp recordings were carried out with TRPM2-HEK293 
cells at 20-22°C using an Axopatch-1D amplifier (Molecular Devices, CA).  Data 
acquisition was performed using pCLAMP Clampex 10.2 software (Molecular Devices).  
Recording electrodes, with a final resistance of 3-5 MΩ when filled with intracellular 
solution (ICS), were prepared from TW150-F3 borosilicate glass (World Precision 
Instruments, FL) using a PP-83 two-stage puller (Narishige, NY).  Electrodes were filled 
with ICS, containing (in mM): 135 cesium gluconate, 10 HEPES buffer, 10 EGTA, 4 
Mg-ATP, 2 MgCl2, 1 CaCl2, and 0.1 ADPR.  Extracellular solution (ECS), consisting of 
(in mM) 140 NaCl, 25 HEPES buffer, 5.4 KCl, 33 glucose, 1 MgCl2, and 2 CaCl2, was 
applied using a SF77B multibarrel perfusion system (Warner Institute, CT).  Since 
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TRPM2 activation requires extracellular Ca2+, CaCl2 in the ECS was replaced with 
equimolar BaCl2 during recordings, as indicated, to abolish TRPM2 current and permit 
channel recovery, while maintaining the total extracellular divalent cation concentration.  
Osmolarity of ICS and ECS were 290-300 and 310-315 mOsm, respectively.  Further, 
ICS and ECS were adjusted to pH 7.3 and 7.4, respectively.  Holding current was 
recorded as a function of time with the membrane potential clamped at -60 mV for all 
recordings.  TRPM2 currents were isolated by exploiting distinctive channel activation 
and inactivation properties.  Currents were activated by ADPR (0.1 mM, in patch 
pipette).  Further, abolition of currents was demonstrated by substitution of extracellular 
Ca2+ with equimolar Ba2+.  Currents were only evoked in doxycycline-induced cells.  
Peak TRPM2 current amplitudes were measured in cells treated with constitutively active 
recombinant Fyn kinase (1 U/mL, in patch pipette) and vehicle-treated control cells.  
TRPM2 currents were recorded using the following protocol: (1) TRPM2 channels were 
initially ‘primed’ by application of Ca2+-containing ECS until 1 nA TRPM2 current was 
observed, (2) TRPM2 current was abolished for 3 minutes by applying Ca2+-free ECS to 
permit channel recovery, (3) TRPM2 current was recorded during application of Ca2+-
containing ECS until TRPM2 current inactivation was observed, (4) TRPM2 channel 
recovery was permitted by abolishing TRPM2 current during a 5 minute application of 
Ca2+-free ECS, (5) a second TRPM2 current was recorded during application of Ca2+-
containing ECS until TRPM2 current inactivation was observed, (6) TRPM2 current was 
again abolished by application of Ca2+-free ECS.  No difference was observed between 
the first and second TRPM2 current peaks.  Results presented here reflect data gathered 
from the first TRPM2 peak current response. 
 
2.3 Generation of TRPM2 constructs 
Wild-type TRPM2 construct: 
Wild-type human TRPM2 (accession number NP_003298.1) was amplified from a 
human cDNA library by polymerase chain reaction (PCR) using KOD Hot Start DNA 
25 
 
 
Polymerase (EMD Biosciences, CA).  Forward and reverse primers for TRPM2 
amplification (listed in table 2.1) were generated from a pIRESpuro-FLAG-TRPM2-WT 
template using Vector NTI software (Invitrogen).  These primers contained NotI and 
AscI substrate sequences for subsequent sub-cloning.  The following thermal profile was 
used for this PCR reaction: (1) 95°C for 2 minutes, (2) 10 cycles of 94°C for 15 seconds, 
60°C (-1°C/cycle) for 15 seconds and 72°C for 120 seconds, and (3) 25 cycles at 94°C 
for 15 seconds, 50°C for 15 seconds, and 72°C for 120 seconds.  The PCR product was 
resolved on a 1% w/v agarose gel containing 0.5 µg/mL ethidium bromide (Sigma-
Aldrich).  The PCR product was extracted from the gel using a GenElute Gel Extraction 
Kit (Sigma-Aldrich) according to the manufacturer’s protocol.  A double restriction 
enzyme digest with NotI and AscI enzymes (New England Biolabs, MA) was carried out 
at 37°C for 2 hours.  Subsequently, digested DNA was purified with a GenElute Gel 
Extraction Kit according to manufacturer’s protocol.  The purified DNA product was 
then ligated into NotI/AscI-digested pIRESpuro-FLAG vector at a 1:5 (vector:insert) 
molar ratio using T4 DNA ligase (New England Biolabs).  The ligated product was 
transformed into JM109 competent cells (Promega, WI) and grown up on LB + 
ampicillin plates overnight at 37°C.  Individual colonies were then expanded in LB + 
ampicillin selection medium, shaking at 250 RPM overnight at 37°C.  Plasmid DNA was 
isolated from pellets using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich) 
according to manufacturer’s protocol.  Incorporation of TRPM2 into pIRESpuro-FLAG 
vector was confirmed by triple restriction digest (AscI/NotI/XhoI, New England Biolabs).  
Positive clones were further confirmed by DNA sequencing (London Regional Genomics 
Centre). 
Site-directed mutagenesis: 
To identify potential tyrosine residue(s) through which Fyn may regulate TRPM2 
phosphorylation and activation, GPS 2.1, a proteomic phosphorylation site prediction tool 
(Xue et al., 2008) was used.  This software compares short amino acid sequence motifs 
on a substrate protein and kinase(s) of interest and predicts high-probability 
phosphorylation sites.  The four identified TRPM2 tyrosine residues with the highest 
prediction scores were Y74, Y142, Y523 and Y1503.  Four mutant human TRPM2 
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constructs were generated by site-directed mutagenesis.   Primers (Sigma-Aldrich; listed 
in table 2.1) were designed using Vector NTI software to amplify wild-type human 
TRPM2 with replacement of the tyrosine residue at amino acid 74 with phenylalanine 
(TAT  TTT) for TRPM2-Y74F, tyrosine 142 to phenylalanine (TACTTC) for 
TRPM2-Y142F, tyrosine 523 to phenylalanine (TACTTC) for Y523F, and tyrosine 
1503 to phenylalanine (TACTTC) for TRPM2-Y1503F.  TRPM2-Y1503F was 
generated using a single PCR reaction, using KOD polymerase, the primers listed in table 
2.1 and pIRESpuro-FLAG-TRPM2-WT as a template.  The following thermal profile 
was used for this PCR reaction: (1) 95°C for 2 minutes, (2) 10 cycles of 94°C for 15 
seconds, 60°C (-1°C/cycle) for 15 seconds and 72°C for 120 seconds, and (3) 25 cycles at 
94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 120 seconds.  Two separate PCR 
reactions were used to generate two fragments of TRPM2-Y74F, TRPM2-Y142F and 
TRPM2-Y523F using KOD polymerase, the primers listed in table 2.1 (TRPM2-Y74F-1 
and TRPM2-Y74F-2; TRPM2-Y142F-1 and TRPM2-Y142F-2; or TRPM2-Y523F-1 and 
TRPM2-Y523F-2) and pIRESpuro-FLAG-TRPM2-WT as a template.  The following 
thermal profile was used for theses PCR reactions: (1) 95°C for 2 minutes, (2) 10 cycles 
at 94°C for 15 seconds, 60°C (-1°C/cycle) for 15 seconds, and 72°C for 10-120 seconds, 
and (3) 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 10-120 
seconds.  Full-length TRPM2-Y74F, TRPM2-Y142F and TRPM2-Y523F were then 
generated using PCR reactions with KOD polymerase, the two fragments of each 
construct and primers listed in table 2.1 (TRPM2-Y74F-1 forward and TRPM2-Y74F-2 
reverse; TRPM2-Y142F-1 forward and TRPM2-Y142F-2 reverse; or TRPM2-Y523F-1 
forward and TRPM2-Y523F-2 reverse).  The following thermal profile was used for 
these PCR reactions: (1) 95°C for 2 minutes, (2) 5 cycles at 94°C for 15 seconds, 60°C (-
1°C/cycle) for 15 seconds, and 72°C for 120 seconds. The reactions were paused to add 
forward and reverse primers, and the PCR reactions were resumed with (3) 5 cycles at 
94°C for 15 seconds, 55°C (-1°C/cycle) for 15 seconds, and 72°C for 120 seconds, and 
(4) 25 cycles at 94°C for 15 seconds, 50°C for 15 seconds, and 72°C for 120 seconds. 
Following mutagenesis, PCR products of TRPM2-Y74F, TRPM2-Y142F, TRPM2-
Y523F and TRPM2-Y1503F were resolved on a 1% w/v agarose gel containing 0.5 
µg/mL ethidium bromide.  The PCR products were extracted from the gel using a  
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Table 2.1: Primers used in generation of wild-type (WT) and mutant (Y74F, Y142F, 
Y523F and Y1503F) TRPM2 constructs. 
Construct Forward Primer (5’  3’) Reverse Primer (5’  3’) 
TRPM2-WT AAACTTAAGCTTGGTACCGA
GCTCGG 
TTACTAGTGGATCCGAAAAGG
GCGA 
TRPM2-Y74F-1 AAACTTAAGCTTGGTACCGA
GCTCGG 
TTTCCACAAAAAACACGCATT
CTTTCT 
TRPM2-Y74F-2 AAAGAATGCGTGTTTTTTGT
GGAAAGTTC 
TTACTAGTGGATCCGAAAAGG
GCGAAT 
TRPM2-Y142F-1 AAACTTAAGCTTGGTACCGA
GCTCGG 
AGACTCGGACGAACTTTTTCA
CCTTCTGG 
TRPM2-Y142F-2 AGAAGGTGAAAAAGTTCGTC
CGAGTCT 
TTACTAGTGGATCCGAAAAGG
GCGA 
TRPM2-Y523F-1 AAACTTAAGCTTGGTACCGA
GCTCGG 
TCCAGGTTCTCGAACAGGTAG
AGCA 
TRPM2-Y523F-2 ACCTTGCTCTACCTGTTCGAG
AACCTG 
TTACTAGTGGATCCGAAAAGG
GCGA 
TRPM2-Y1503F AAACTTAAGCTTGGTACCGA
GCTCGG 
TATCGAGAATTCTCAGAAGTG
AGCCCCG 
 
GenElute Gel Extraction Kit according to the manufacturer’s protocol.  A double 
restriction enzyme digest with NotI and AscI enzymes was carried out at 37°C for 2 
hours.  Subsequently, digested DNA was purified with GenElute Gel Extraction Kit 
according to the manufacturer’s protocol.  The purified DNA product was then ligated 
into NotI/AscI-digested pIRESpuro-FLAG vector at a 1:5 (vector:insert) molar ratio 
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using T4 DNA ligase.  The ligated product was transformed into JM109 competent cells 
and grown up on LB + ampicillin plates overnight at 37°C.  Individual colonies were then 
expanded in LB + ampicillin selection medium, shaking at 250 RPM overnight at 37°C.  
Plasmid DNA was isolated from pellets using the GenElute Plasmid Miniprep Kit 
according to manufacturer’s protocol.  Incorporation of TRPM2 mutants into pIRESpuro-
FLAG vector was confirmed by triple restriction digest (AscI/NotI/XhoI).  Positive 
clones were further confirmed by DNA sequencing (London Regional Genomics Centre). 
 
2.4 Transfection 
24 hours prior to transfection, TRPM2-HEK293 cells or HEK293T cells were plated on 
100 mm culture dishes at approximately 30% cell confluence, resulting in approximately 
60% cell confluence at the time of transfection.  TRPM2 expression was induced in 
TRPM2-HEK293 cells by administration of doxycycline (1.0 µg/mL) to cells 18-24 hours 
prior to transfection.  Cells were transfected with JetPRIMETM (Polyplus Transfection, 
NY) according to the manufacturer’s protocol.  Briefly, 10 µg total DNA (2 µg of 
pIRESpuro-HA, Fyn-WT, FynY531F or Fyn-K299M, where indicated; 2 µg TRPM2-
WT, TRPM2-Y74F, TRPM2-Y142F, TRPM2-Y523F or TRPM2-Y1503F, where 
indicated; 1 µg green fluorescent protein (PLB-GFP); and 5-7 µg pcDNA3.1) was added 
to 500 µL JetPRIMETM buffer (Polyplus Transfection) in a sterile microtube and mixed 
by vortexing.  12.5 µL JetPRIMETM enzyme (Polyplus Transfection) was added to 
microtube and vortexed for 10 seconds. After a 10 minute incubation at room 
temperature, 500 µL transfection mix was added drop-wise to plates of cells, and plates 
were gently mixed and incubated for four hours at 37°C and 5% CO2.  Following this 
incubation, the transfection media was removed and replaced with DMEM + 10% FBS + 
1 µg/µL doxycycline.  Subsequently, cells were incubated at 37°C and 5% CO2 for 48 
hours prior to lysis. 
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2.5 Immunoprecipitation and Western blotting 
After transfection, TRPM2-HEK293 cells or HEK293T cells were homogenized in lysis 
buffer (1% NP-40, 1% sodium deoxycholate, 150 mM NaCl, 20 mM Tris-HCl (pH 7.4), 
1 mM EDTA (pH 8.0), Complete Mini protease inhibitor cocktail (Roche, Germany) and 
HALT phosphatase inhibitor cocktail (Pierce, IL)).  Homogenates were centrifuged 
(16,100 rcf at 4°C for 30 min) to remove insoluble debris.  Samples containing 1.0 mg of 
protein in 500 µL lysis buffer were incubated overnight with 20 µL packed anti-FLAG 
M2 affinity gel beads (Sigma, MO).   Beads were subjected to three centrifugation-wash 
cycles with lysis buffer to remove elements not associated with beads.  Proteins were 
eluted and denatured by incubating (30 min at 37°C) with 2x Laemmli sample loading 
buffer  (4% SDS, 125 mM Tris-HCl (pH 6.8), 20% glycerol, 0.02% bromophenol blue 
and 5% β-mercaptoethanol).  Subsequently, samples were centrifuged (5,000 rcf at 4°C 
for 5 min).  Eluates were resolved by 8% SDS-PAGE and transferred to nitrocellulose 
membranes.  Blots were subsequently probed with rabbit anti-Fyn (H-80; Santa Cruz, 
CA), mouse anti-phosphotyrosine (4G10; Upstate Biotechnology, NY), HRP-conjugated 
mouse anti-FLAG (Sigma-Aldrich) or mouse anti-β-actin (Sigma-Aldrich) antibodies 
followed by appropriate HRP-conjugated secondary detection antibodies.  Blots were 
visualized using SuperSignal West Pico enhanced chemiluminscence (Thermo Scientific, 
IL) and VersaDocTM Imaging System (Bio-Rad, CA).  
 
2.6 Drugs and peptides 
The sources of materials for this study are as follows: NaCl, glucose, CaCl2, MgCl2, 
BaCl2, gluconic acid, CsOH, ADPR, Mg(ATP)2, Ponceau S stain, GenElute Gel 
Extraction Kit, GenElute Plasmid Miniprep Kit, GenElute Plasmid Midiprep Kit, 
Dulbecco’s Modified Eagle Medium, Fetal Bovine Serum (Sigma-Aldrich), Supersignal 
West Pico Stable Peroxide Solution, Supersignal West Pico Luminal/Enhancer, BCA 
Protein Assay Kit (Thermo Scientific), KCl, HEPES, EGTA, EDTA, SDS, glycerol, 
bromophenol blue, β-mercaptoethanol, NP-40, sodium deoxycholate, Tris, HCl (Bioshop, 
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ON), Mini-complete protease inhibitor cocktail tablets (Roche), HALTTM phosphatase 
inhibitor cocktail (Pierce), JM109 bacteria (Promega), KOD polymerase (EMD 
Millipore), doxycycline (Pfizer, ON), JetPRIME (Polyplus), AscI, NotI, XhoI, CIP (New 
England Biolab), and recombinant active Fyn kinase (Upstate Biotechnology). 
 
2.7 Data analysis and statistics 
Electrophysiological data analysis was performed using pCLAMP Clampfit 10.2 software 
(Molecular Devices).  Densitometric analysis of Western blots was conducted using 
Image Lab 3.0 (Beta 5) software (Bio-Rad).  All data are presented as mean ± SEM  
Statistical analysis was conducted using GraphPad Prism® 5 (GraphPad Software, CA).  
Where indicated, means were compared using an unpaired Student’s t-tests or one-way 
ANOVA followed by Tukey’s post-hoc test.  For all tests, P<0.05 was considered 
significant. 
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3.1 Regulation of TRPM2 currents by Fyn kinase 
Our first experimental objective was to assess whether Fyn functionally regulates 
TRPM2 channels.  Preliminary evidence from the literature and our lab suggested a 
potential role for Fyn in regulation of TRPM2 channels.  Zhang et al. (2007) showed that 
TRPM2 activation induced by H2O2 treatment could be reduced by PP2, a non-specific 
SFK inhibitor.  Thus, one or more SFK is likely responsible for augmenting TRPM2 
currents.  We previously demonstrated that TRPM2 currents could be evoked in cultured 
hippocampal neurons by repeated applications of NMDA in the absence of ADPR 
(MacDonald/Jackson lab, unpublished).  Further, repeated NMDA applications resulted 
in increased TRPM2 currents over time – an effect that was abolished by inhibition of 
Fyn signaling using a short interfering peptide, Fyn(39-57) (Appendix A, Fig. S2; 
MacDonald/Jackson lab, unpublished).  This Fyn-mediated augmentation of TRPM2 
currents could be due to an increase in NMDAR currents, a direct enhancement of 
TRPM2 activation or both.  In this study, we assessed whether Fyn regulates TRPM2 
currents in HEK293 cells expressing inducible TRPM2 (TRPM2-HEK293 cells; cell line 
described in section 2.1).  Notably, HEK293 cells do not express endogenous NMDARs 
(Domingues et al., 2006), so enhancement of TRPM2 currents by NMDAR is not a 
confounding variable in this experimental paradigm.   
A whole-cell voltage-clamp electrophysiological recording protocol was designed to 
record TRPM2 currents in TRPM2-HEK293 cells (detailed in section 2.2).  TRPM2-
HEK293 cells contain an inducible protein expression system, in which TRPM2 
expression can be induced by treatment of cells with doxycycline 18-24 hours prior to 
recording.  After inducing TRPM2 expression, TRPM2 currents were evoked in TRPM2-
HEK293 cells.  Characteristic of TRPM2 activation, inward currents were activated by 
ADPR (0.1 mM, in patch pipette) in the presence of extracellular Ca2+ (2 mM) (Fig. 
3.1A).  Further, these currents were abolished by application of Ca2+-deficient ECS.  
Notably, because currents mediated by some cation channels, such as TRPM7, are  
  
Figure 3.1: Fyn potentiates TRPM2 currents in TRPM2
(A) Representative whole
mM, in patch pipette) in presence of recombinant Fyn (1 U/mL) or vehicle (in
pipette). Horizontal bars above graphs indicate presence of Ca
currents were abolished in absence of extracellular Ca
(B) Summary bar graph showing potentiation of TRPM2 currents by Fyn.
presented as mean ± SEM
test, *P < 0.05. 
 
 
-HEK293 cells.
-cell recordings of TRPM2 currents activated by ADPR (0.1 
2+
 (2 mM) in ECS. TRPM2 
2+
. Holding potential was 
 (n=8 per condition). Statistical analysis: unpaired Student’s t
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dependent on extracellular divalent cation concentration (Chen et al., 2010), Ca2+ (2 mM) 
was substituted with Ba2+ (2 mM) in Ca2+-deficient ECS to maintain a constant total 
divalent cation concentration. These findings are consistent with previously reported 
activation and inactivation properties of TRPM2. 
To determine whether Fyn regulates TRPM2 currents, recombinant Fyn kinase (1 U/mL) 
or vehicle was delivered to the cell interior by inclusion in the patch pipette.  Peak 
TRPM2 current amplitudes were compared in the presence of Fyn or vehicle.  TRPM2 
current amplitudes were significantly increased in cells treated with intracellular Fyn      
(-5470 ± 425 pA, n=8) relative to vehicle-treated control cells (-3743 ± 478 pA, n=8) 
(P<0.05) (Fig. 3.1B). This result suggests that Fyn potentiates TRPM2 currents in an 
NMDAR-independent manner.  However, the molecular mechanism underlying this 
regulation remains unclear.  Subsequent experiments were focused on defining the 
mechanism through which Fyn regulates TRPM2 function. 
 
3.2 Expression of Fyn and TRPM2 in TRPM2-HEK293 cells  
Our next objective was to characterize the molecular mechanism by which Fyn may 
regulate TRPM2 function.  Specifically, we investigated whether Fyn induces tyrosine 
phosphorylation of TRPM2 and whether Fyn physically interacts with TRPM2 (see 
sections 3.3 and 3.4, respectively).  A combination of biochemistry and molecular 
biology techniques were employed to study these relationships between Fyn and TRPM2.  
In each of these experiments, TRPM2-HEK293 cells were induced to express TRPM2 by 
pre-treatment with doxycycline 24 hours before lysis.  Additionally, in each experiment, 
these cells were transfected with one of three constructs designed to induce expression of 
wild-type Fyn (WT), constitutively active Fyn (Y531F) or inactive Fyn (K299M) or 
empty vector (transfection protocol detailed in section 2.4).  The expression of Fyn and 
TRPM2 relative to β-actin was compared between each transfection condition. 
First, Fyn expression was quantified relative to β-actin. No Fyn immunoreactivity was 
detected in empty vector-transfected cells (Fig. 3.2A,C).  This suggests that endogenous  
A. 
Figure 3.2: Expression of TRPM2 and Fyn in TRPM2
Expression of TRPM2 (FLAG) and Fyn in TRPM2
with Fyn constructs (wild
K299M) or empty vector (EV).  
of Fyn, FLAG and β-actin. 
decreased in cells expressing Y531F relative to EV and K299M. 
showing that Fyn expression was 
expression was increased in cells expressing Y531F relative to K299M.  Expression of 
FLAG and Fyn were quantified relative to 
(n=3 per condition). Statistical analysis: one
Tukey’s post-hoc test.  Identical letters (a, b, c) indicate no significant difference between 
groups (P < 0.05). 
 
 
 
B. 
C. 
-HEK293 cells.
-HEK293 cells transiently transfected 
-type, WT; constitutively active, Y531F; dominant negative, 
(A) Representative blot showing input expression levels 
(B) Summary bar graph showing that TRPM2 expression is 
(C) Summary bar graph 
not detected in EV-transfected cells.  Further, Fyn 
β-actin. Data are presented as mean ± SEM
-way repeated-measures ANOVA with 
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Fyn is either absent from TRPM2-HEK293 cell lysates or below the detection threshold 
under these experimental conditions.  In this regard, previous studies have suggested that 
HEK293 cells do express endogenous Fyn (Wu et al., 2007).  Post-transfection Fyn 
expression levels in cells expressing constitutively active Fyn (Y531F), wild-type Fyn 
(WT) and inactive Fyn (K299M) were fairly comparable and all significantly higher than 
empty vector-transfected cells (Fig. 3.2A,C).  Although Fyn expression was higher in 
cells expressing constitutively active Fyn (Y531F) relative to inactive Fyn (K299M) 
(P<0.05) (Fig. 3.2A,C), considering the inherent variability of post-transfection protein 
expression levels, a relatively consistent amount of Fyn was detected in cells expressing 
constitutively active Fyn (Y531F), wild-type Fyn (WT) and inactive Fyn (K299M). 
Next, TRPM2 expression was quantified relative to β-actin.  Such quantification allowed 
us to assess whether the activation status Fyn affects TRPM2 protein levels.  A relatively 
high variability in TRPM2 expression levels was observed in cells expressing 
constitutively active Fyn (Y531F), wild-type Fyn (WT), inactive Fyn (K299M) and 
empty vector.  TRPM2 expression was significantly decreased in cells expressing 
constitutively active Fyn (Y531F) relative to empty vector and inactive Fyn (K299M) 
(P<0.05) (Fig. 3.2A,B).  Although not statistically significantly, wild-type Fyn (WT)-
expressing cells exhibited TRPM2 expression levels higher than cells expressing 
constitutively active Fyn (Y531F) and lower than those expressing inactive Fyn (K299M) 
or empty vector (Fig. 3.2A,B).  Taken together, these observations suggest that the 
expression level of TRPM2 in TRPM2-HEK293 cells depends on the activation state of 
Fyn.  Specifically, increased Fyn activity corresponds with decreased TRPM2 expression.  
However, the mechanism underlying this phenomenon is unclear at present. 
 
3.3 Tyrosine phosphorylation of TRPM2 induced by Fyn 
kinase 
We were interested in determining whether Fyn induces tyrosine phosphorylation of 
TRPM2.  Notably, tyrosine phosphorylation of TRPM2 has been shown to coincide with 
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increased TRPM2 activation, intracellular Ca2+ and apoptotic cell death in HEK293 cells 
expressing TRPM2 (Zhang et al., 2007).  However the kinase responsible for this 
phosphorylation has not been identified.  We have shown that Fyn augments TRPM2 
channel function (Fig. 3.2).  Given these findings and the fact that Fyn is a tyrosine 
kinase, it follows that the mechanism by which Fyn potentiates TRPM2 currents likely 
involves tyrosine phosphorylation of TRPM2 by Fyn.  Here, we investigated whether Fyn 
induces tyrosine phosphorylation of TRPM2.   
To determine whether Fyn induces tyrosine phosphorylation of TRPM2, we assessed the 
relative amount of TRPM2 tyrosine phosphorylation in TRPM2-HEK293 cells co-
expressing TRPM2 as well as wild-type Fyn (WT), constitutively active Fyn (Y531F), 
inactive Fyn (K299M) or empty vector.  First, TRPM2-HEK293 cells were induced to 
express TRPM2 by pre-treatment of cells with doxycycline 24 hours before lysis.  These 
cells were also transfected with one of three constructs designed to induce expression of 
wild-type Fyn (WT), constitutively active Fyn (Y531F) or inactive Fyn (K299M) or 
empty vector.  Tyrosine phosphorylation was subsequently analyzed by 
immunoprecipitation and Western blotting (detailed in section 2.5).  Briefly, cells were 
lysed in the presence of protease and phosphatase inhibitors.  Lysates were separated by 
SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted for tyrosine 
phosphorylation and FLAG (total TRPM2).   
Although lysate TRPM2 expression was substantially reduced in cells expressing 
constitutively active Fyn (Y531) relative to the other transfection conditions studied (Fig. 
3.2), immunoprecipitation of FLAG-tagged TRPM2 constructs yielded a reasonably 
consistent amount of TRPM2 for each transfection condition (Fig. 3.3).  Tyrosine 
phosphorylation of TRPM2 was detected for cells transfected with all Fyn constructs and 
empty vector.  The fact that TRPM2 tyrosine phosphorylation was observed in cells 
transfected with empty vector and inactive Fyn (K299M) suggests that there is some 
basal TRPM2 phosphorylation that is attributable to endogenous Fyn or other tyrosine 
kinases.  However, the physiological importance of this phosphorylation and whether it 
occurs at sites that are important for TRPM2 activation remain unknown.  Tyrosine 
phosphorylation of TRPM2 was significantly increased in TRPM2-HEK293 cells  
Figure 3.3: Fyn induces tyrosine phosphorylation of TRPM2.
Representative blot (A) and summary bar graph (
phosphorylation was increased in TRPM2
Fyn (Y531F) relative to empty vector (EV), wild
(K299M).  Data are presented as mean ± SEM
one-way repeated-measures AN
indicate no significant difference between groups (
A. 
B. 
 
 
 
 
B) showing that TRPM2 tyrosine 
-HEK293 cells expressing constitutively active 
-type Fyn (WT) and inactive Fyn 
 (n=4 per condition). Statistical analysis: 
OVA with Tukey’s post-hoc test.  Identical letters (a, b) 
P < 0.05). 
38 
 
 
39 
 
 
expressing constitutively active Fyn-Y531F relative to wild-type Fyn-WT, inactive Fyn-
K299M and EV (P<0.05) (Fig. 3.3).  This observation suggests that Fyn induces tyrosine 
phosphorylation of TRPM2 in an activation state-dependent manner.  Specifically, 
increased Fyn activity corresponds with increased TRPM2 phosphorylation.  The 
simplest mechanism to explain this phenomenon is direct phosphorylation of TRPM2 by 
Fyn, but the actual mechanism remains unclear at present. Notably, the phosphorylated 
TRPM2 tyrosine residue(s) responsible for modulation of channel function by Fyn have 
not been identified. 
 
3.4 Physical interaction between Fyn kinase and TRPM2 
Next, we wanted to determine whether Fyn physically interacts with TRPM2.  Interaction 
between these proteins may be necessary or facilitative for Fyn-induced tyrosine 
phosphorylation of TRPM2.  This interaction may involve direct protein-protein binding 
of Fyn to TRPM2.  Alternatively, both proteins could be part of a larger protein complex, 
in which Fyn anchors to TRPM2 through one or more adaptor proteins.  Regardless of 
whether this interaction is direct or indirect, such physical interaction may facilitate Fyn 
regulation of TRPM2 by stabilizing a configuration in which Fyn is maintained in close 
physical proximity to TRPM2. 
To determine whether Fyn physically interacts with TRPM2, we assessed the relative 
amount of Fyn that co-immunoprecipitated with Fyn in TRPM2-HEK293 cells co-
expressing TRPM2 as well as wild-type Fyn (WT), constitutively active Fyn (Y531F), 
inactive Fyn (K299M) or empty vector.  First, TRPM2-HEK293 cells were induced to 
express TRPM2 by pre-treatment of cells with doxycycline 24 hours before lysis.  These 
cells were also transfected with one of three constructs designed to induce expression of 
wild-type Fyn (WT), constitutively active Fyn (Y531F) or inactive Fyn (K299M) or 
empty vector.  Co-immunoprecipitation of Fyn with TRPM2 was subsequently assessed 
by immunoprecipitation and Western blotting (detailed in section 2.5).  Briefly, cells 
were lysed in the presence of protease and phosphatase inhibitors.  Lysates were 
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separated by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted for 
Fyn and TRPM2.   
Immunoprecipitates from lysates expressing wild-type Fyn (WT), constitutively active 
Fyn (Y531F) and inactive Fyn (K299M) exhibited immunoreactivity for Fyn, whereas 
immunoprecipitates from empty vector-transfected cells displayed no Fyn 
immunoreactivity (Fig. 3.4).  This is consistent with the finding that no endogenous Fyn 
was detectable in empty vector-transfected TRPM2-HEK293 cell lysates (Fig. 3.2).  
Interestingly, co-immunoprecipitation of constitutively active Fyn (Y531F) with TRPM2 
was significantly higher than wild-type Fyn (WT), inactive Fyn (K299M) and empty 
vector (P<0.05) (Fig. 3.4).  This suggests that the amount of interaction between Fyn and 
TRPM2 may be dependent on the activation status of Fyn.  Importantly, co-
immunoprecipitation is not capable of distinguishing whether the interaction between Fyn 
and TRPM2 is direct or indirect (i.e. mediated by one or more adaptor proteins).  So long 
as the intermolecular binding stringency within a multi-protein complex is sufficiently 
high, immunoprecipitation of one protein in the complex may co-precipitate other 
physically associated proteins.  Regardless, this observation suggests that Fyn physically 
associates with TRPM2, which may be required or facilitative for Fyn regulation of 
TRPM2 channels. 
 
3.5 Expression of Fyn and TRPM2 in HEK293T cells  
Our next objective was to identify potential regulatory TRPM2 tyrosine residues through 
which Fyn may regulate TRPM2 function.  To identify such regulatory tyrosine residues, 
a combined bioinformatic and genetic approach was used (detailed in section 2.3).  
Briefly, GPS 2.1 phosphorylation prediction software (Xue et al., 2011) was used to 
identify probable phosphorylation sites for Fyn on TRPM2 based on kinase-substrate  
Figure 3.4: Fyn physically interacts with TRPM2.
Representative blot (A) and summary bar graph (
immunoprecipitation of Fyn (wild
negative, K299M) with TRPM2. Co
higher than empty vector (EV), WT and K299M. 
(n=3 per condition). Statistical analysis: one
Tukey’s post-hoc test.  Identical letters (a, b) indicate no significant difference between 
groups (P < 0.05). 
A. 
B. 
 
 
 
 
B) demonstrating co-
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complimentarity of short sequence motifs.  The four identified TRPM2 tyrosine residues 
with the highest prediction scores were Y74, Y142, Y523 and Y1503.  Using site-
directed mutagenesis, four mutant human TRPM2 constructs were generated in which 
each of these candidate tyrosine residues was mutated to phenylalanine to ablate possible 
phosphorylation at that residue (TRPM2-Y74F, -Y142F, -Y523F and -Y1503F). 
Subsequently, we investigated whether each of these TRPM2 mutant proteins (Y74F, 
Y142F, Y523F and Y1503F) exhibited reduced tyrosine phosphorylation relative to wild-
type (WT) TRPM2 (section 3.6).  Additionally, we assessed whether each of these 
TRPM2 mutations (Y74F, Y142F, Y523F and Y1503F) affected the physical interaction 
between Fyn and TRPM2 (section 3.7).  A combination of biochemistry and molecular 
biology techniques were employed to study these relationships between Fyn and TRPM2.  
In each of these experiments, HEK293T cells were co-transfected to induce expression of 
a Fyn construct (constitutively active, Y531F; or empty vector) and a TRPM2 construct 
(wild-type, WT; or mutant, Y74F, Y142F, Y523F or Y1503F) (generation of TRPM2 
constructs described in section 2.3).  The expression of Fyn and TRPM2 relative to β-
actin was compared between each transfection condition. 
First, Fyn expression was quantified relative to β-actin.  As observed in TRPM2-HEK293 
cells, little or no Fyn immunoreactivity was detected in empty vector-transfected 
HEK293T cells (Fig. 3.2A,C).  Post-transfection Fyn expression levels in HEK293T cells 
expressing constitutively active Fyn (Y531F) as well as wild-type (WT) or mutant 
(Y74F, Y142F, Y523F or Y1503F) TRPM2 were not significantly different from each 
other and all significantly higher than empty vector-transfected cells (Fig. 3.5A,C).  
Considering the inherent variability of post-transfection protein expression levels, a 
relatively consistent amount of Fyn was detected in cells expressing constitutively active 
Fyn (Y531F), regardless of which TRPM2 construct was expressed. 
Next, TRPM2 expression was quantified relative to β-actin.  Such quantification allowed 
us to assess whether the TRPM2 mutations examined or Fyn activation affects TRPM2 
expression levels.  Post-transfection TRPM2 expression were relatively consistent in 
HEK293 cells expressing constitutively active Fyn (Y531F) or empty vector as well as 
wild-type (WT) or mutant (Y74F, Y142F, Y523F or Y1503F) TRPM2 (Fig. 3.5A,B).   
Figure 3.5: Expression of TRPM2 and Fyn in HEK293T cells.
Expression of TRPM2 (FLAG) and Fyn in HEK293T cells co
construct (wild-type, WT; or mutant, Y74F, Y142F, Y523F, Y1503F) and a Fyn 
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Notably, TRPM2 expression levels were not significantly different between any of the 
transfection conditions studied (Fig. 3.5B).  Thus, considering the inherent variability of 
post-transfection protein expression levels, a relatively consistent amount of TRPM2 was 
detected in HEK293T cells, regardless of which TRPM2 construct was expressed. 
 
3.6  Tyrosine phosphorylation of wild-type and mutant 
TRPM2 by Fyn kinase 
As previously described, tyrosine phosphorylation of TRPM2 coincides with increased 
TRPM2 activation, intracellular Ca2+ and apoptotic cell death in HEK293 cells 
expressing TRPM2 (Zhang et al., 2007).  However, the phosphorylated tyrosine residue 
on TRPM2 that is responsible for its regulation by Fyn has not been identified.  Here, we 
discuss an experiment that was designed to determine whether Fyn induces 
phosphorylation of four candidate TRPM2 tyrosine residues (TRPM2-Y74, -Y142,          
-Y523 and -Y1503) that were identified using GPS 2.1 phosphorylation site prediction 
software (Xue et al., 2011). 
As previously noted, four mutant TRPM2 constructs were generated in which each of 
these four candidate tyrosine residues was individually mutated to a phenylalanine.  Since 
this mutation effectively ablates phosphorylation of the corresponding residue, it is 
expected that if one or more of these four candidate tyrosine residues is phosphorylated 
by Fyn, then the corresponding mutant(s) should exhibit reduced Fyn phosphorylation 
relative to wild-type TRPM2.  Thus, here we investigated whether phosphorylation of 
TRPM2-Y74, -Y142, -Y523 and -Y1503 are induced by Fyn.  To determine whether Fyn 
induces tyrosine phosphorylation of these candidate TRPM2 tyrosine residues, we 
assessed the relative amount of TRPM2 tyrosine phosphorylation in HEK293T cells co-
expressing constitutively active Fyn (Y531F) or empty vector as well as wild-type (WT) 
or mutant (Y74, Y142, Y523 and Y1503) TRPM2.  First, HEK293T cells were co-
transfected to induce expression of one Fyn construct (constitutively active, Y531F; or 
empty vector) and one TRPM2 construct (wild-type, WT; or mutant, Y74, Y142, Y523, 
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Y1503).  Tyrosine phosphorylation was subsequently analyzed by immunoprecipitation 
and Western blotting (detailed in section 2.5).  Briefly, cells were lysed in the presence of 
protease and phosphatase inhibitors.  Lysates were separated by SDS-PAGE, transferred 
to nitrocellulose membranes and immunoblotted for tyrosine phosphorylation and FLAG 
(total TRPM2).   
Tyrosine phosphorylation of TRPM2 was detected in all cells, regardless of which Fyn 
and TRPM2 constructs were expressed.  The fact that TRPM2 tyrosine phosphorylation 
was observed in cells transfected with empty vector suggests that there is some basal 
TRPM2 phosphorylation that is attributable to endogenous Fyn or other tyrosine kinases.  
However, the physiological importance of this phosphorylation and whether it occurs at 
sites that are important for TRPM2 activation remain unknown.  There were no 
significant differences in tyrosine phosphorylation of TRPM2 between the wild-type and 
mutant TRPM2 constructs examined (Fig. 3.6).  Thus, Fyn-induced phosphorylation of 
wild-type and mutant TRPM2 was not detected under these experimental conditions.  It is 
possible that this experimental paradigm was not sufficiently sensitive to detect 
phosphorylation of these candidate regulatory sites or that Fyn does not actually induce 
phosphorylation of these specific sites. 
 
3.7 Physical interaction between Fyn kinase and wild-type 
or mutant TRPM2 
Next, we wanted to determine whether the candidate regulatory TRPM2 tyrosine residues 
(Y74, Y142, Y523 and Y1503) are important for the physical interaction between Fyn 
and TRPM2.  Interaction between these proteins may be necessary or facilitative for Fyn-
induced tyrosine phosphorylation of TRPM2.  Moreover, tyrosine phosphorylation could 
be necessary for the physical interaction between Fyn and TRPM2.  However, the regions 
of Fyn and TRPM2 that are responsible for mediating their physical interaction have not 
yet been identified.  Notably, phosphorylated tyrosine residues may provide potential 
binding sites for the SH2 domain of Fyn.  Previously discussed results demonstrate that  
Figure 3.6: Fyn does not induce
Y523 and -Y1503 
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Fyn co-immunoprecipitates with TRPM2, implying a physical interaction between these 
molecules (see Fig. 3.4).  This experiment was designed to determine whether the four 
candidate TRPM2 tyrosine residues (TRPM2-Y74, -Y142, -Y523 and -Y1503) are 
important for the physical interaction between Fyn and TRPM2.  As previously noted, 
four mutant TRPM2 constructs were generated in which each of these four candidate 
tyrosine residues was mutated to a phenylalanine.  Since this mutation effectively ablates 
phosphorylation of the corresponding residue, it is expected that if phosphorylation of 
one or more of these four candidate tyrosine residues is important for the physical 
interaction of Fyn with TRPM2, then the corresponding mutant(s) should exhibit reduced 
Fyn co-immunoprecipitation relative to wild-type TRPM2.  Thus, here we investigated 
whether phosphorylation of TRPM2-Y74, -Y142, -Y523 and -Y1503 are important for 
physical interaction between Fyn and TRPM2.  In HEK293T cells co-expressing 
constitutively active Fyn (Y531F) or empty vector as well as wild-type (WT) or mutant 
(Y74, Y142, Y523 and Y1503) TRPM2, we assessed the relative amount of Fyn co-
immunoprecipitation with TRPM2.  First, HEK293T cells were co-transfected to induce 
expression of one Fyn construct (constitutively active, Y531F; or empty vector) and one 
TRPM2 construct (wild-type, WT; or mutant, Y74, Y142, Y523, Y1503).  Fyn co-
immunoprecipitation was subsequently analyzed by TRPM2 pull-down and Western 
blotting (detailed in section 2.5).  Briefly, cells were lysed in the presence of protease and 
phosphatase inhibitors.  Lysates were separated by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted for Fyn and FLAG (total TRPM2). 
Immunoprecipitates from lysates expressing constitutively active Fyn (Y531F) showed 
immunoreactivity for Fyn, whereas immunoprecipitates from empty vector-transfected 
cells displayed no Fyn immunoreactivity (Fig. 3.7).  There were no significant 
differences in the amount of Fyn that immunoprecipitated with TRPM2 between the 
transfection conditions examined (Fig. 3.7B).  This observation suggests that the four 
candidate TRPM2 tyrosine residues identified are not essential for the interaction 
between Fyn and TRPM2.  Further, these results provide no evidence that suggests that 
these residues play a role in mediating this interaction.  It is possible that this 
experimental paradigm was not sufficiently sensitive to detect changes in the amount of  
Figure 3.7: TRPM2-Y74, 
between TRPM2 and Fyn.
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protein-protein interaction between wild-type and mutant TRPM2 proteins or that these 
candidate tyrosine residues do not contribute to the physical interaction between Fyn and 
TRPM2. 
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DISCUSSION 
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4.1 Summary of key findings 
In this study, we investigated a potential physical and functional relationship between 
Fyn and TRPM2.  Specifically, we investigated whether Fyn regulates TRPM2 currents, 
induces tyrosine phosphorylation of TRPM2 and physically interacts with TRPM2.  
Subsequently, we attempted to identify tyrosine residues on TRPM2 through which Fyn 
may regulate its channel activity.  Notably, each experiment utilized a HEK293 cell 
variant (TRPM2-HEK293 or HEK293T) expressing both Fyn and TRPM2.  Intracellular 
application of recombinant Fyn potentiated TRPM2 currents in TRPM2-HEK293 cells.  
Tyrosine phosphorylation of TRPM2 was increased in TRPM2-HEK293 cells transfected 
to increase Fyn expression, and the amount of phosphorylation detected was related to the 
activation state of Fyn.  Further, Fyn directly co-immunoprecipitated with TRPM2, and 
the amount of Fyn that co-immunoprecipitated was related to the activation state of Fyn.  
Experiments designed to determine whether four candidate TRPM2 tyrosine residues 
(TRPM2-Y74, Y142, Y523 and Y1503) were phosphorylated by Fyn did not lead to 
identification of potential regulatory tyrosines.  In summary, we have demonstrated that 
Fyn physically interacts with TRPM2, induces tyrosine phosphorylation of TRPM2, and 
increases currents mediated by TRPM2.  
 
4.2 Regulation of TRPM2 by Fyn kinase 
In this study, we have shown that Fyn physically interacts with TRPM2, induces tyrosine 
phosphorylation of TRPM2 and regulates TRPM2 function in HEK293 cell line variants 
(HEK293T cells and TRPM2-HEK293 cells) co-expressing Fyn and TRPM2.  These 
results suggest that Fyn is an important regulator of TRPM2 in HEK293 cells.  However, 
the molecular mechanism through which Fyn regulates TRPM2 remains an open 
question.  Moreover, because protein expression, distribution and activation patterns 
differ between cell types, mechanisms of TRPM2 regulation may differ between HEK293 
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cells and other cell lines.  However, results from parallel studies conducted in the 
MacDonald/Jackson lab (unpublished) suggest that Fyn also regulates TRPM2 function 
in neurons.   
In these studies, cultured hippocampal neurons (21-28 days in vitro) were used to assess 
whether currents from endogenous TRPM2 are regulated by recombinant Fyn.  In this 
experiment, TRPM2 currents were activated using a voltage ramp protocol.  Briefly, 
TRPM2 currents were evoked by voltage ramps (±100 mV over 500 ms) applied every 10 
s throughout the recording in the presence of exogenous ADPR (0.3 mM; in patch 
pipette).  In cultured neurons, recombinant Fyn (1 U/mL; in patch pipette) significantly 
potentiated TRPM2 currents compared to vehicle-treated controls (Appendix A, Fig. S1).  
This result coincides with the finding that Fyn potentiates TRPM2 in TRPM2-HEK293 
cells (Fig. 3.1), providing additional support for Fyn as a regulator of TRPM2 function. 
To examine the role of Fyn’s unique domain (Fyn-UD), a short peptide (Fyn(39-57)) was 
designed, whose sequence corresponds with part of Fyn-UD (AA 39-57).  Fyn(39-57) 
presumably disrupts Fyn activity by binding to proteins that interact with Fyn-UD, and 
competitively displacing their interactions with Fyn.  Notably, Fyn(39-57) and an 
analogous Src-interfering peptide (Src(40-58)), were shown to disrupt Fyn- and Src-
mediated regulation of NR2B and NR2A subunit-containing NMDARs, respectively 
(Yang et al., 2011).  Thus, Fyn(39-57) specifically interferes with Fyn and not Src.  
Fyn(39-57) was used to examine the role of Fyn in the regulation of TRPM2 function in 
neurons (MacDonald/Jackson lab, unpublished).  In cultured hippocampal neurons, 
repeated applications of NMDA (0.1 mM; 1/60 s) in the absence of exogenous ADPR 
induced TRPM2 activation and a resultant increase in holding current over 25 minutes 
(Appendix A, Fig. S2).  However, intracellular application of Fyn(39-57) (25 ng/mL; in 
patch pipette) significantly reduced this TRPM2 activation and increase in holding 
current (Appendix A, Fig. S2).  This result reaffirms the notion that Fyn potentiates 
TRPM2 currents in cultured neurons.  Further, this result suggests that the Fyn-UD is 
important for the regulation of TRPM2 by Fyn in neurons.  The UD of Src has been 
implicated as an interaction-mediating domain (Gingrich et al., 2004).  Similarly, Fyn-
UD may mediate protein-protein interaction between Fyn and TRPM2, either directly or 
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through one or more adaptor proteins.  Alternatively, Fyn-UD could be important for the 
interaction of Fyn with other related signaling proteins.  However, the function of Fyn-
UD has not yet been described. 
 
4.3 Identification of TRPM2 tyrosine residue(s) responsible 
for Fyn modulation 
Converging evidence suggests that TRPM2 activation is regulated by tyrosine 
phosphorylation.  Zhang et al. (2007) showed that TRPM2 activation in response to 
oxidative stress was significantly reduced by the tyrosine phosphatase PTPL1 as well as 
by tyrosine kinase inhibitors, including PP2 – a non-specific SFK inhibitor.  These results 
suggest that a tyrosine phosphorylation event, which is likely mediated by a SFK, 
regulates TRPM2 activation.  However, the identity of the SFK member(s) that regulate 
TRPM2 has not previously been explored.  We have shown here that Fyn induces 
tyrosine phosphorylation of TRPM2 and potentiates TRPM2 function.  Further, the 
degree of TRPM2 phosphorylation is related to the activation state of Fyn.  For example, 
TRPM2-HEK293 cells expressing constitutively active Fyn-Y531F exhibited 
significantly more TRPM2 tyrosine phosphorylation that cells transfected with empty 
vector, wild-type Fyn or inactive Fyn-K299M constructs (Fig. 3.3).  This finding supports 
the notion that Fyn induces tyrosine phosphorylation of TRPM2. 
However, the regulatory tyrosine residue(s) on TRPM2, whose phosphorylation results in 
increased TRPM2 currents, remain unidentified.  Identification of these regulatory sites is 
critical for defining the activation properties of TRPM2.  Because TRPM2 has been 
implicated as a mediator of cell death in a number of oxidative stress-related degenerative 
diseases, decreasing TRPM2 activation may be a therapeutic strategy to reduce cell death 
in such conditions.  By extension, pharmacological agents that disrupt phosphorylation 
events that potentiate TRPM2 channel activation may reduce TRPM2 activation and 
associated cell death. 
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Several strategies have been employed for identifying phosphorylation sites for specific 
kinase-substrate combinations.  For example, phosphorylation sites may be determined 
by Edman phosphate-release sequencing of 32P-radiolabelled phosphoproteins.  This 
technique involves purifying a phosphopeptide by antiphosphotyrosine antibody affinity 
chromatography and reverse phase high performance liquid chromatography followed by 
sequential release and sequencing of each amino acid from the N-terminus while 
monitoring for 32P-radiolabelled tyrosine residues (Smart et al., 1981; Wagner et al., 
1991).  Alternatively, phosphorylation sites may be identified using mass spectrometry.  
In this approach, a phosphopeptide is enriched, using techniques such as immobilized 
metal affinity chromatography, followed by mass analysis using a mass spectrometer 
(Munton et al., 2007).  Additionally, a bioinformatic prediction approach may be used to 
identify tyrosine phosphorylation sites.  This approach utilizes phosphorylation site 
prediction software, which predicts high-probability phosphorylation sites based on 
substrate consensus sequences that have been established or identified in the literature for 
a kinase of interest (Phanstiel et al., 2011; Xue et al., 2008).  Notably, as phosphorylation 
prediction software begins to incorporate three-dimensional structural information about 
kinases and substrates of interest into prediction algorithms, more accurate predictions of 
phosphorylation sites will be possible.  Additionally, a genetic approach may be used to 
identify sites of tyrosine phosphorylation.  This approach utilizes site-directed 
mutagenesis of candidate tyrosine residues followed by an assay to confirm loss of 
tyrosine phosphorylation, such as Western blotting with a phosphotyrosine-specific 
antibody or monitoring 32P-radiolabelling of phosphoproteins (Daubner et al., 1992; 
Nakamura et al., 2000).  A limitation of this approach is that a given protein may contain 
multiple tyrosine residues, which would require time-consuming mutagenesis of each 
tyrosine residue.  For example, TRPM2 contains 31 intracellular tyrosine residues (13 N-
terminal, 15 C-terminal and 3 intracellular loop) that could be phosphorylated by Fyn.  
Notably, each of these approaches has been used successfully in the literature and could 
be used to investigate which TRPM2 tyrosine residue(s) may be phosphorylated by Fyn. 
In this study, a genetic approach was combined with a bioinformatic prediction approach 
to identify the TRPM2 tyrosine residue(s) responsible for channel regulation by Fyn.  
Rather than sequentially mutate all 31 intracellular TRPM2 tyrosine residues, GPS 2.1 
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phosphorylation site prediction software (Xue et al., 2010) was utilized to identify high-
probability Fyn substrate sites, thus increasing the efficiency of identifying regulatory 
phosphorylation sites.  To assess the ability of GPS 2.1 software to successfully predict 
tyrosine phosphorylation sites, predicted Fyn phosphorylation sites were compared to 
literature-established phosphorylation sites for known Fyn substrates: NMDAR subunit 
NR2B and microtubule-associated protein tau.  GPS 2.1 predicted that Fyn 
phosphorylates NMDAR subunit NR2B at residues Y1472, Y1336 and Y1252, which 
were identified as the major Fyn phosphorylation sites on NR2B by Nakazawa et al. 
(2001) using site-directed mutagenesis and Western blotting.  Further, GPS 2.1 predicted 
that Fyn phosphorylates tau (isoform 2) at residues Y18 and Y197, which were identified 
as the major Fyn phosphorylation sites on tau by Scales et al. (2011) using mass 
spectrometry and two-dimensional phosphopeptide mapping.  Notably, GPS 2.1 software 
has been successfully used by several authors to make initial predictions of 
phosphorylation sites, which were subsequently confirmed by other techniques (Ishiguro 
et al., 2010; Wang et al., 2012).  These findings provided some confidence in the ability 
of GPS 2.1 software to accurately predict Fyn substrate phosphorylation sites. 
Using GPS 2.1 phosphorylation site prediction software, the four identified TRPM2 
tyrosine residues with the highest prediction scores were Y74, Y142, Y523 and Y1503 
(Fig. 4.1).  For each of these potential regulatory tyrosine residues, a TRPM2 mutant 
construct was designed and synthesized using site-directed mutagenesis.  For each 
mutant, the potential regulatory tyrosine was substituted with phenylalanine.  
Phenylalanine is chemically identical to tyrosine, except that it lacks an aromatic 
hydroxyl group, which is essential for phosphorylation.  Thus, mutation of tyrosine to 
phenylalanine effectively ablates phosphorylation at the targeted residue.  By extension, 
if phosphorylation of these residues is indeed important for Fyn regulation of TRPM2, 
such point mutations should abolish Fyn regulation of TRPM2.  Thus, it is expected that 
if Fyn induces phosphorylation of one or more of these tyrosine residues, 
phosphorylation of the corresponding mutant TRPM2 protein(s) should be reduced or 
ablated.  HEK293T cells co-expressing a Fyn construct (Fyn-Y531F or EV) and a 
TRPM2 construct (TRPM2-WT, -Y74F, -Y142F, -Y523F, or -Y1503F) were used to 
assess whether these TRPM2 mutations reduced or ablated Fyn-induced tyrosine  
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Figure 4.1: Potential regulatory TRPM2 tyrosine residues. 
Linear schematic of human TRPM2 protein indicating four tyrosine residues (Y74, Y142, 
Y523 and Y1503; indicated by arrows), which were identified as probable 
phosphorylation targets of human Fyn kinase using GPS 2.1 software.  Four mutant 
human TRPM2 constructs were prepared by site-directed mutagenesis, in which these 
tyrosine residues were individually substituted with phenylalanine. 
 
phosphorylation of TRPM2.  However, the amount of Fyn-induced phosphorylation of 
TRPM2 was not significantly different in any of the TRPM2 mutants relative to wild-
type TRPM2 (Fig. 3.6). 
There are several possible reasons that Fyn-induced TRPM2 phosphorylation was not 
found to be significantly different in mutant relative to wild-type TRPM2.  Firstly, it is 
possible that phosphorylation of one or more of the candidate sites analyzed here is/are 
induced by Fyn, but this phosphorylation was not effectively detected in this study.  
Failure to detect phosphorylation of a specific tyrosine residue may be attributable to the 
use of a non-specific phosphotyrosine antibody (mouse anti-phosphotyrosine 4G10; 
Upstate Biotechnology, NY).  This antibody does not specifically recognize the tyrosine 
residue of interest.  As such, if phosphorylation of the site of interest is relatively low 
compared to the total phosphorylation of TRPM2, it may be difficult to resolve minute 
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differences in phosphorylation of an individual tyrosine of interest.  This problem is 
compounded by the fact that Fyn may phosphorylate multiple tyrosine residues within 
TRPM2.  Alternatively, Fyn may induce tyrosine phosphorylation of a residue that was 
not predicted by GPS 2.1 software.  Supplementary use of another technique to assess 
tyrosine phosphorylation, such as mass spectrometry or amino acid sequencing (as 
described above), could be employed to better assess whether Fyn induces 
phosphorylation of these candidate regulatory TRPM2 tyrosine residues. 
Zhang et al. (2007) demonstrated that phosphorylation of TRPM2 at an as-yet-
unidentified tyrosine residue closely coincides with increased TRPM2 channel activation.  
However, the significance of such tyrosine phosphorylation has not yet been described.  
For example, TRPM2 phosphorylation could directly cause an increase in channel gating, 
facilitate channel activation by another protein or be unrelated to channel function.  
Details on potential mechanisms by which Fyn-induced tyrosine phosphorylation of 
TRPM2 may regulate TRPM2 function are discussed section 4.5. 
To assess whether these point mutations of the four potential regulatory TRPM2 tyrosine 
residues (TRPM2-Y74F, -Y142F, -Y523F and -Y1503F) affect TRPM2 regulation by 
Fyn kinase, an additional experiment could be designed.  Whole-cell voltage-clamp 
recordings could be conducted in HEK293T cells as previously described (section 2.2).  
Cells would be transfected with one of five TRPM2 constructs (TRPM2-WT, -Y74F,       
-Y142F, -Y523F, -Y1503F).  Recombinant active Fyn or vehicle would be delivered 
intracellularly by inclusion in the patch pipette.  It is expected that if Fyn regulates 
TRPM2 function through one or more of these tyrosine residues, Fyn-induced 
potentiation of TRPM2 currents would be reduced for the corresponding mutant TRPM2 
protein(s).  Taken together, these experiments may lead to the identification of TRPM2 
tyrosine residue(s) whose phosphorylation by Fyn coincides with increased TRPM2 
activation. 
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4.4 Physical interaction between Fyn and TRPM2 
Protein-protein interaction between Fyn and TRPM2 may be important for regulation of 
TRPM2 function by Fyn.  The results of the present study show that Fyn physically 
interacts with TRPM2 (Fig. 3.4).  Notably, Fyn-TRPM2 interaction was demonstrated in 
cells expressing constitutively active Fyn-Y531F, wild-type Fyn and inactive Fyn-
K299M, but not in empty vector-transfected cells (Fig. 3.4).  Further, the extent of this 
interaction may be related to the activation state of Fyn; significantly more constitutively 
active Fyn-Y531F co-immunoprecipitated with TRPM2 than wild-type Fyn or inactive 
Fyn-K299M (Fig. 3.4).  These results suggest that protein-protein interaction occurs 
between Fyn and TRPM2.  As previously noted, potentiation of TRPM2 currents by Fyn 
may contribute to dysregulation of calcium homeostasis and cell death in several 
oxidative stress-related degenerative diseases.  If the regulation of TRPM2 by Fyn is 
dependent on the physical interaction between these molecules, then pharmacologically 
disrupting this interaction may be a strategy to reduce the contribution of TRPM2 to such 
degeneration.  Clearly, defining the nature of the interaction between these molecules 
would be critical for designing pharmacological interaction-disrupting agents.  For 
example, protein-protein interaction between Fyn and TRPM2 could be disrupted using a 
short interfering peptide designed in a similar manner to Fyn(39-57), with an identical 
amino acid sequence to the interaction-mediating domain of Fyn or TRPM2.  Such a 
peptide, if administered at a sufficiently high concentration, would be expected to 
competitively bind to Fyn or TRPM2 (depending on which protein was used as a 
template for the peptide sequence) and disrupt the physical interaction between Fyn and 
TRPM2.  Consequently, if this interaction is important for the functional regulation of 
TRPM2 channel activity by Fyn, then Fyn-mediated potentiation of TRPM2 channel 
activity would also be disrupted by this peptide. 
Whether the physical interaction between Fyn and TRPM2 is direct or indirect (i.e. 
mediated through one or more scaffolding proteins) is unclear at present.  In this study, 
co-immunoprecipitation was used to assess whether or not there is a physical interaction 
between these proteins.  This technique involves sequestering one protein with an agarose 
bead-linked antibody.  Subsequently, the bead-antibody-antigen complex is separated 
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from any unbound components by several alternating centrifugation and wash cycles.  
The antigen of interest and any physically associated proteins are then eluted and 
analyzed by Western blotting.  Importantly, this technique is not capable of 
distinguishing whether Fyn binds directly to TRPM2 or whether both proteins are part of 
a larger complex of physically associated proteins.  However, the use of relatively high-
stringency immunoprecipitation and wash buffers increases the probability that 
interaction detected by co-immunoprecipitation is direct.  The immunoprecipitation and 
wash buffers used here were relatively stringent compared to those used in other co-
immunoprecipitation studies (1% NP-40, 1% sodium deoxycholate; detailed in section 
2.5).  Whether the interaction is direct or indirect, provided the stringency of binding is 
sufficiently high, pull-down of antibody-sequestered TRPM2 would result in co-
immunoprecipitation of Fyn.  Along these lines, Sato et al. (2008) showed that post-
synaptic density-93 (PSD-93) mediates the physical interaction between Fyn (but not Src) 
and NMDARs.  PSD-93 was shown to mediate phosphorylation of NMDARs by Fyn as 
well as synaptic localization of Fyn (Sato et al., 2008).  Similarly, Gingrich et al. (2004) 
showed that the physical interaction between Src (but not Fyn) and NMDARs was 
mediated by NADH dehydrogenase subunit 2 (ND2), which functions as an adaptor 
protein in this complex.  In this complex, ND2 is essential for Src regulation of NMDAR 
function (Gingrich et al., 2004).  Similarly, there may be one or more adaptor proteins 
that physically link Fyn to TRPM2.  Alternatively, Fyn may associate directly with 
TRPM2.   
The domains of Fyn and TRPM2 that are responsible for mediating their physical 
interaction have not yet been identified.  As described previously, Fyn contains several 
domains that may mediate interactions with other proteins.  For example, the SH3 
domain of Fyn mediates interactions with proline-rich sequences that contain PxxP 
motifs (where ‘x’ represents any amino acid) (Salter & Kalia, 2004).  Analysis of the 
amino acid sequence of TRPM2 reveals six such motifs: AA 544-547, 551-554, 575-578, 
1078-1081, 1248-1251 and 1324-1327.  However, whether these motifs mediate the 
interaction between Fyn and TRPM2 has not been investigated.  The SH2 domain of Fyn 
mediates interactions with specific sequences that contain phosphotyrosine residues 
(Salter & Kalia, 2004).  TRPM2 sequence analysis reveals 31 tyrosine residues (13 N-
60 
 
 
terminal, 15 C-terminal and 3 intracellular loop) that could act as docking sites for Fyn-
SH2 binding.  As previously described, all SFK members contain an N-terminal unique 
domain, which shares a low degree of sequence homology with other SFK members 
(Salter & Kalia, 2004).  Because of the low sequence homology, this region could be 
important for determining the unique actions of each SFK.  The unique domain of Src has 
been shown to mediate its physical interaction with ND2 (Gingrich et al., 2004).  By 
extension, it is possible that the unique domain of Fyn could similarly mediate protein-
protein interaction with TRPM2.  However, the role of Fyn’s unique domain has not yet 
been characterized.  As described above, in cultured hippocampal neurons, intracellular 
application of Fyn(39-57) (25 ng/mL) through its inclusion in the patch pipette 
significantly reduced the TRPM2 activation and increase in holding current evoked by 
repeated NMDA applications (Appendix A, Fig. S2).  Since Fyn(39-57) specifically 
disrupts interactions mediated by Fyn’s unique domain, it stands to reason that this 
domain is critical for regulation of TRPM2 function by Fyn.  However, this does not 
necessarily imply that physical interaction between Fyn and TRPM2 is mediated by 
Fyn’s unique domain.  For example, the unique domain could mediate a physical 
association of Fyn to an adaptor protein or regulate Fyn activity or substrate specificity 
through an as-yet-undescribed mechanism. 
Experiments could be designed to identify the binding domains that mediate the 
interaction between Fyn and TRPM2.  As previously noted, Fyn(39-57) disrupts protein-
protein interactions mediated by Fyn’s N-terminal unique domain.  Thus, it stands to 
reason that if Fyn(39-57) disrupted the interaction between Fyn and TRPM2, it is 
mediated by Fyn’s unique domain.  To identify Fyn’s binding site on TRPM2, several 
short FLAG-epitope-tagged fragments of TRPM2 could be generated.  HEK293 cells 
would then be transfected to induce expression of these constructs as well as 
constitutively active Fyn-Y531F.  After lysis, SDS-PAGE and transfer to nitrocellulose 
membranes, FLAG immunoprecipitates would be immunoblotted for Fyn.  The TRPM2 
fragment that demonstrated immunoreactivity for Fyn would represent the domain that 
physically interacts with Fyn.  Alternatively, if the interaction is mediated by Fyn-SH2, 
then sequentially mutating each tyrosine residue to phenylalanine and determining 
whether Fyn physically interacts with each TRPM2 mutant would lead to identification of 
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the interaction-mediating tyrosine residue.  Similarly, if the interaction between Fyn and 
TRPM2 is mediated by Fyn-SH3, then sequentially mutating each proline-rich PxxP 
motif and determining whether Fyn physically interacts with each TRPM2 mutant would 
lead to identification of the interaction-mediating PxxP motif. 
Physical interaction between Fyn and TRPM2 may be dependent on Fyn activation.  
Notably, significantly more constitutively active Fyn-Y531F co-immunoprecipitated with 
TRPM2 than wild-type Fyn or inactive Fyn-K299M (Fig. 3.4).  Mechanistically, this 
observation could be attributable to the different conformations of active and inactive 
Fyn.  In its inactive conformation, Fyn forms a closed, inaccessible bundle, which is 
stabilized by intramolecular interactions of its SH2 domain with tyrosine 531 and its SH3 
domain with a PxxP motif within its linker region (Liu et al., 1993; Superti-Furga et al., 
1993).  Alternatively, in its active conformation, Fyn is characterized by an open, 
accessible structure (Cowan-Jacob et al., 2005).  It is possible that the interaction between 
Fyn and TRPM2 is more stable when Fyn is in an active, open conformation.  
Alternatively, protein-protein interaction between Fyn and TRPM2 may be dependent on 
TRPM2 phosphorylation.  As previously described, the SH2 domain of Fyn binds to 
amino acid sequences that contain phosphorylated tyrosine residues.  By extension, it is 
possible that tyrosine phosphorylation of TRPM2 by Fyn may regulate the interaction of 
Fyn with TRPM2 by providing SH2 binding sites.  This mechanism would also explain 
the finding that constitutively active Fyn-Y531F interacts with TRPM2 to a greater 
degree than wild-type Fyn or inactive Fyn-K299M (Fig. 3.4); increased Fyn activation 
results in increased TRPM2 tyrosine phosphorylation, which may provide more binding 
sites for Fyn and consequently, more interaction between Fyn and TRPM2.  A similar 
mechanism was proposed for the interaction between Fyn and tau.  Specifically, Usardi et 
al. (2011) showed that the SH2 domain of Fyn interacts with tyrosine 18 of tau – a 
reported target of Fyn phosphorylation (Hernandez et al., 2009).  Thus, Fyn regulates its 
own interaction with tau through tyrosine phosphorylation.  Whether the candidate 
regulatory TRPM2 tyrosine residues identified using GPS 2.1 software (TRPM2-Y74,     
-Y142, -Y523 and -Y1503) are important for the physical interaction between Fyn and 
TRPM2 remains an open question.  Notably, if one or more of these tyrosine residues are 
important for the physical interaction between Fyn and TRPM2, the corresponding 
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tyrosine to phenylalanine mutants should exhibit reduced co-immunoprecipitation of Fyn 
with TRPM2.  To assess the importance of the these candidate TRPM2 regulatory 
tyrosines,  HEK293T cells were co-transfected with active Fyn (Fyn-Y531F) or empty 
vector as well as each of five TRPM2 constructs (TRPM2-WT, -Y74F, -Y142F, -Y523F, 
-Y1503F).  Immunoprecipitation of TRPM2 and immunoblotting were carried out as 
described previously (see section 2.5).  The amount of Fyn that co-immunoprecipitated 
with each mutant TRPM2 construct was not significantly different for each of the four 
mutant TRPM2 constructs relative to wild-type TRPM2 (Fig. 3.7).    Thus, point 
mutations of the proposed regulatory TRPM2 tyrosine residues had no discernible effect 
on the physical interaction between Fyn and TRPM2.  This observation suggests that 
these candidate TRPM2 phosphorylation sites are not critical for the interaction between 
Fyn and TRPM2.  Post-transfection lysate expression levels of TRPM2 and Fyn relative 
to β-actin in HEK293T cells are shown in Fig 3.5.   
The physiological significance of the physical interaction between Fyn and TRPM2 
remains unclear at present.  It is likely that anchoring of Fyn to TRPM2 facilitates 
channel regulation.  However, it is also possible that the regulation of TRPM2 by Fyn is 
unrelated to the physical interaction between these proteins.    
 
4.5 Mechanism of TRPM2 regulation by Fyn kinase 
We have shown that TRPM2 currents are increased by intracellular application of 
recombinant Fyn.  Fyn-mediated augmentation of TRPM2 activity could result from 
increased expression, increased surface localization and/or altered gating properties of 
TRPM2.  Characterizing the mechanism through which Fyn regulates TRPM2 is 
important for understanding the basic functional properties of TRPM2 channels and for 
designing means to disrupt the functional regulation of TRPM2 by Fyn. 
To assess whether TRPM2 expression is modulated by Fyn, lysate TRPM2 expression 
levels were compared in TRPM2-HEK293 cells co-expressing TRPM2 as well as wild-
type Fyn, constitutively active Fyn (Y531F), inactive Fyn (K299M) or empty vector.  
63 
 
 
Interestingly, despite the finding that TRPM2 currents are augmented by Fyn (Fig. 3.1), 
expression of active Fyn-Y531F resulted in a decrease in TRPM2 expression relative to 
inactive Fyn-K299M and empty vector (Fig. 3.2).  Notably, there are important 
differences between the experimental paradigm used to study TRPM2 currents and that 
used to study TRPM2 expression, phosphorylation and protein-protein interaction.  In the 
electrophysiological protocol used to study TRPM2 currents, recombinant active Fyn was 
delivered transiently to the intracellular compartment for the duration of each recording 
by inclusion in the patch pipette.  Alternatively, in the biochemistry protocol used to 
study TRPM2 expression, phosphorylation and protein-protein interaction, Fyn 
expression was induced by transfecting cells 48 hours prior to cell lysis with constructs 
that drive Fyn expression.  Thus, the electrophysiology technique solely accounts for 
transient effects of Fyn on TRPM2, whereas the biochemistry technique accounts only 
for more long-term effects of Fyn on TRPM2.  To study the short-term effects of Fyn on 
TRPM2 expression, TRPM2-HEK293 cells could be induced to express TRPM2, 
transfected to induce Fyn expression, and lysed at various time points after transfection.  
Subsequent Western blotting for Fyn and TRPM2 would reveal a profile of TRPM2 and 
Fyn expression levels over time. 
It is possible that Fyn influences TRPM2 activity by altering TRPM2 surface expression.  
Surface biotinylation could be used to assess whether Fyn modulates the surface 
localization of TRPM2.  Surface expression of TRPM2 would be compared in HEK293 
cells expressing biotinylated TRPM2 as well as wild-type Fyn, constitutively active Fyn 
(Y531F), inactive Fyn (K299M) or empty vector.  If Fyn influences TRPM2 activity by 
altering its surface localization, it is expected that cells expressing active Fyn-Y531F 
would exhibit higher TRPM2 surface expression than the other conditions. 
Alternatively, it is possible that Fyn influences TRPM2 activity by altering the gating 
properties of TRPM2 channels.  Experiments could be designed to investigate such 
mechanisms.  For example, whole-cell voltage-clamp electrophysiology could be used to 
determine whether Fyn affects ADPR sensitivity, Ca2+ sensitivity or Ca2+-dependent 
inactivation of TRPM2.  Notably, the roles of TRPM2 tyrosine phosphorylation and 
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physical interaction in the regulation of TRPM2 function are discussed in sections 4.3 
and 4.4, respectively.   
 
4.6 Specificity of TRPM2 regulation by Fyn kinase 
Since there is a high degree of sequence homology and common domain structure 
between SFK members (Salter and Kalia, 2004), it is possible that other SFKs may also 
regulate TRPM2 function.  Notably, Zhang et al. (2007) demonstrated that PP2 reduced 
H2O2-induced TRPM2 phosphorylation, Ca2+ influx and cell death.  However, because 
PP2 is a non-specific SFK inhibitor, this effect cannot be attributed to any specific SFK 
member.  To determine whether the observed regulation of TRPM2 channels is Fyn-
specific, experiments could be designed to determine whether Src, another SFK member, 
also regulates TRPM2.  First, whether intracellular application of recombinant active Src 
(via the patch pipette), regulates TRPM2 currents in TRPM2-HEK293 cells could be 
assessed.  Additionally, the Fyn- and Src-specific interfering peptides Fyn(39-57) and 
Src(40-58) could be applied intracellularly (via the patch pipette) to determine whether 
each influences TRPM2 currents regulated by endogenous SFKs, which are expressed in 
HEK293 cells.   
To determine whether the increase in TRPM2 tyrosine phosphorylation observed is Fyn-
specific, a construct that drives expression of constitutively active Src (Src-Y527F) could 
be utilized.  Tyrosine phosphorylation of TRPM2 would be compared in FLAG-
immunoprecipitates of TRPM2-HEK293 cells co-expressing TRPM2 as well as Src-
Y527F, Fyn-Y531F or empty vector.  If phosphorylation of TRPM2 is Fyn-specific, cells 
expressing Fyn-Y531F will exhibit more TRPM2 tyrosine phosphorylation than those 
expressing Src-Y527F or empty vector.  Alternatively, if Src also induces tyrosine 
phosphorylation of TRPM2, then it is expected that Src-Y527F would exhibit more 
tyrosine phosphorylation than empty vector-transfected cells. 
To determine whether the interaction between Fyn and TRPM2 is Fyn-specific, TRPM2-
HEK293 cells expressing TRPM2 could be transfected with a construct driving 
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expression of Src-Y527F or Fyn-Y531F.  If the physical interaction observed is Fyn-
selective, FLAG-immunoprecipitates of cells expressing Fyn-Y531F should exhibit 
immunoreactivity as previously demonstrated, and cells expressing Src-Y527F should not 
show Src immunoreactivity. 
 
4.7 TRPM2, Fyn and NMDA receptor signaling 
Fyn kinase, TRPM2 and NMDARs may form a functional signaling complex whose 
activity is augmented in several oxidative stress-related degenerative diseases.  Co-
activation of these molecules may synergistically increase Ca2+ influx, resulting in 
activation of cell death pathways.  Functional relationships between Fyn and NMDAR, as 
well as TRPM2 and NMDARs have been previously described in the literature.  In this 
study, we describe a novel relationship between Fyn and TRPM2.  We propose that co-
activation of TRPM2, Fyn and NMDARs could lead to pathological dysregulation of 
intracellular Ca2+ homeostasis and neuronal death in oxidative stress-related degenerative 
diseases. 
Functional relationships between Fyn and NMDAR, as well as TRPM2 and NMDARs 
have been described previously.  Fyn has previously been shown to phosphorylate 
NMDARs, resulting in cytotoxic Ca2+ overload (Ittner et al., 2010).  Intracellular Ca2+ 
associated with NMDAR activation has also been shown to activate TRPM2 (Olah et al., 
2009).  Thus, TRPM2 channels may be co-activated with NMDARs.   
In this study, we have described a novel relationship between Fyn and TRPM2.  
Specifically, we have shown that Fyn physically interacts with TRPM2 (Fig. 3.4), 
induces tyrosine phosphorylation of TRPM2 (Fig. 3.3) and potentiates currents mediated 
by TRPM2 (Fig. 3.1).  Importantly, Fyn was also shown to enhance NMDAR-activated 
TRPM2 currents in cultured hippocampal neurons (Appendix A, Fig. S1; 
MacDonald/Jackson lab, unpublished).  In this experimental context, Fyn may have 
potentiated TRPM2 currents by directly phosphorylating TRPM2 currents or by 
augmentation of NMDARs.  Since HEK293 cells do not express endogenous NMDAR 
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(Domingues et al., 2006), in this system, TRPM2 currents were augmented by Fyn 
through an NMDAR-independent mechanism.  Increased intracellular Ca2+ resulting from 
activation of Ca2+-permeable NMDAR and TRPM2 channels may further potentiate 
TRPM2 current since TRPM2 is activated in a concentration-dependent manner by 
intracellular Ca2+ (Du et al., 2009a). This is compounded by the fact that Fyn can 
potentiate currents mediated by both TRPM2 and NMDAR.  Taken together, these results 
suggest that co-activation of TRPM2, Fyn and NMDAR may result in pathological Ca2+ 
overload and consequent cell death in response to oxidative stress. 
 
4.8 Oxidative stress and signaling of TRPM2, Fyn and 
NMDAR 
In independent studies, activation of TRPM2, Fyn and NMDAR have been demonstrated 
in response to oxidative stress.  Two independent studies published in 2002 showed that 
in HEK293 cells transfected to induce expression of TRPM2, treatment with oxidative 
stressors, such as H2O2, induces activation of TRPM2 channels and consequent increases 
in [Ca2+]i (Hara et al., 2002; Wehage et al., 2002).  Sanguinetti et al. (2003) demonstrated 
that Fyn autophosphorylation and kinase activation occur in response to oxidative 
stressors, such as H2O2.  Activation of Fyn (but not Src or Yes) results in tyrosine 
phosphorylation of caveolin-1 in response to oxidative stress (Sanguinetti et al., 2003).  
Further, treatment of rat hippocampal slices with H2O2 results in a transient reduction in 
glutamatergic synaptic transmission, which is followed by a delayed increase in NMDAR 
activation (Avshalumov & Rice, 2002). Moreover, sustained activation of NMDARs can 
induce activation of NADPH oxidase 2 (NOX2), an enzyme that produces superoxide 
and induces oxidative stress and cell death in local cells (Reyes et al., 2012).  Taken 
together, TRPM2, Fyn and NMDAR are all activated in response to oxidative stress. 
Further, TRPM2, Fyn and NMDAR activation have been independently implicated as 
mediators of cell death.  TRPM2 activation in response to extracellular H2O2 treatment 
and intracellular ADPR administration has been shown to mediate cell death in HEK293 
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cells expressing TRPM2 (Hara et al., 2002; Wehage et al., 2002).  Fyn has been also been 
implicated as a mediator of cell death.  For example, in a cytolytic hybridoma cell line, 
Fyn was shown to mediate cell death signal transduction of the apoptosis-inducing Fas 
receptor (Atkinson et al., 1996).  Additionally, in a T cell hybridoma cell line, Fyn 
activation was shown to be critical for T-cell receptor-induced caspase activation and 
consequent apoptosis (Ricci et al., 2001).  Excessive activation of NMDAR has also been 
shown to induce cellular influx of pathological levels of intracellular Ca2+ and evoke cell 
death (Ittner et al., 2010).  Specifically, GluN2B subunit-containing NMDARs have been 
implicated in neuronal apoptosis (Hardingham et al., 2002).  Thus, TRPM2, Fyn and 
NMDARs have all been implicated as contributors to cell death. 
TRPM2, Fyn and NMDAR overactivation have been implicated in oxidative stress-
related degenerative diseases.  For example, each of these molecules have been 
implicated in the pathogenesis of Alzheimer’s disease (AD).  Although somewhat 
controversial, one theory of AD maintains that increased oxidative stress in the brains of 
affected patients is critical for the pathogenesis of AD (Christen, 2000).  Overactivation 
of TRPM2 has been suggested to contribute to cell death in a variety of oxidative stress-
related degenerative diseases, such as AD (Jiang et al., 2009).  Mechanistically, oxidative 
stress causes mitochondrial dysfunction, resulting in production of ADPR, which in turn 
activates TRPM2 (Perraud et al., 2005).  Fyn has also been implicated in AD 
pathogenesis.  Shirazi and Wood (1993) showed that Fyn expression is increased in 
subsets of hippocampal neurons in AD patients relative to age-matched unaffected 
controls.  Fyn-deficient mice display reduced Aβ-induced neuronal death (Lambert et al., 
1998).  Further, overexpression of Fyn results in increased Aβ-induced synaptic damage 
and cognitive deficits (Chin et al., 2005).  Additionally, NMDAR has been implicated in 
AD pathogenesis.  For example, Shankar et al. (2007) showed that activation of NMDAR 
is absolutely required for Aβ-induced synaptic damage (Shankar et al., 2007).  Therefore, 
TRPM2, Fyn and NMDAR have all been implicated as pathogenic factors in oxidative 
stress-related degenerative diseases, such as AD.  Although no positive relation between 
Fyn, TRPM2 and NMDAR has been demonstrated, we propose that co-activation of these 
molecules could result in pathological increases in [Ca2+]i  and cell death in response to 
oxidative stress through the mechanism described in section 4.7.   
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Whether the findings of these in vitro experiments are physiologically meaningful 
depends on whether they accurately represent what occurs in vivo.  All of the experiments 
conducted in this study utilized HEK293 variant cell lines to study TRPM2.  These cell 
lines are useful for studying TRPM2 for several reasons.  Firstly, TRPM2 activation has 
been demonstrated in response to stimulation of NMDA receptors (Olah et al., 2009).  
Because HEK293 cells do not express NMDARs, their potential confounding influence 
on TRPM2 function is nonexistent.  Also, because there are few effective commercially 
available antibodies for TRPM2, it is difficult to study neuronal TRPM2 using 
biochemical techniques.  However, using a HEK293 cell expression system, such as the 
inducible TRPM2-HEK293 cell line or transfection of HEK293T cells with plasmids 
driving TRPM2 expression, TRPM2 can be linked to a FLAG epitope tag and detected 
using an antibody directed against the FLAG epitope.  Although HEK293 cell lines 
facilitate the study of TRPM2 channels, they may function differently than cells in an in 
vivo context.  That Fyn was also shown to potentiate TRPM2 currents in cultured 
hippocampal neurons supports the regulatory role for Fyn on TRPM2 that is described in 
this study (Appendix A, Fig. S1).  However, because these neurons were isolated from 
the hippocampus and cultured, they may also function differently than they would in 
vivo.   
If Fyn does augment TRPM2 function in vivo as described here in vitro, and this 
augmentation of TRPM2 currents significantly contributes to cell death in oxidative 
stress-related degenerative diseases, then pharmacologically disrupting this regulation 
could provide a potential therapeutic strategy.  This regulation could be disrupted by 
designing a short interfering peptide that mimics an interaction-mediating domain of Fyn 
or TRPM2.  Such a peptide would function by competitively binding to Fyn or TRPM2 
and interfering with the normal interaction between these proteins.  Notably, such a 
peptide could be tagged with a transactivator of transcription (TAT)-tag, which allows a 
protein of interest to be effectively taken up from the extracellular medium into the 
intracellular compartment.   
TRPM2 was previously shown to be critical for NMDAR-dependent long-term 
depression (LTD) (Xie et al., 2011).  To assess whether Fyn-mediated regulation of 
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TRPM2 contributes to synaptic plasticity, the effect of this peptide on LTD and long-term 
potentiation (LTP) in hippocampal slices could assessed.  Further, the effect of this 
peptide in animal models of oxidative stress-related diseases could be assessed.   
To study the potential role of TRPM2 in AD, TRPM2+/- mice were crossed with 
APPswePS1dE9 mice, a transgenic model of AD that expresses the Swedish amyloid 
precursor protein (APP) mutation and a deletion of presinilin 1 (PS1) in exon 9 
(MacDonald/Jackson lab, unpublished; Malm et al., 2011).  It was demonstrated that 
knockout of TRPM2 rescued cognitive deficits observed in Barnes Maze and Morris 
Water Maze in the AD mouse model after 12 and 15 months (MacDonald/Jackson lab, 
unpublished).  To determine whether the interaction between Fyn and TRPM2 
contributes to degeneration in AD, the effect of administering the Fyn/TRPM2-
interfering peptide to APPswePS1dE9 mice could be assessed. 
 
4.9 Significance of work 
The present study was designed to characterize a signaling pathway through which Fyn 
may modulate TRPM2 function.  Fyn was shown to physically interact with TRPM2 
(Fig. 3.4), induce tyrosine phosphorylation of TRPM2 (Fig. 3.3) and potentiate currents 
mediated by TRPM2 (Fig. 3.1).  Further, an attempt was made to identify regulatory 
tyrosine residues through which Fyn may regulate TRPM2 function.  However, the latter 
experiment did not yield any potential regulatory sites.   
We propose that by augmenting TRPM2 activity, Fyn kinase may potentiate cellular Ca2+ 
overload and neuronal death in oxidative stress-related degenerative diseases.  TRPM2 is 
expressed in neuronal subpopulations (Olah et al., 2009) as well as several other cell 
types, including immune cells, endothelial cells, cardiomyocytes, pancreatic β-cells and 
others (Jiang et al., 2010). TRPM2 overactivation has been implicated in the pathogenesis 
of several oxidative stress-related neurodegenerative, cardiovascular, inflammatory and 
endocrine disorders (Jiang et al., 2010).  Further, Fyn expression is nearly ubiquitous 
(Sanguinetti et al., 2003).  It follows that, in several cell types, potentiation of TRPM2 
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activation by Fyn may contribute to cell death.  Pharmacologically disrupting Fyn 
regulation of TRPM2 may be a useful therapeutic strategy to reduce degeneration such 
pathological conditions. 
 
4.10 Overall conclusions 
In the present study, we have characterized a novel functional and physical relationship 
between TRPM2 channels and Fyn kinase.  Fyn was shown to physically interact with 
TRPM2, and the degree of interaction between these molecules was dependent on the 
activation state of Fyn (Fig. 3.4).  Fyn was also shown to induce tyrosine phosphorylation 
of TRPM2, and the amount of phosphorylation was related to the activation state of Fyn 
(Fig. 3.3).  Lastly, Fyn was shown to augment currents mediated by TRPM2 channels 
(Fig. 3.1).  Under conditions of oxidative stress, co-activation of Fyn and TRPM2 may 
result in excessive activation of TRPM2 channels, pathological increases in [Ca2+]i and 
consequent cell death. 
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Appendix A: Supplementary Figures 
 
 
Figure S1: Fyn potentiates TRPM2 currents in cultured hippocampal neurons. 
(A) Representative whole-cell recordings of TRPM2 currents activated by voltage ramps 
in the presence of ADPR (0.3 mM, in patch pipette) as well as recombinant Fyn (1 U/mL) 
or vehicle (in patch pipette). Dashed bars above graphs indicate times at which Ca2+ (2 
mM)-containing ECS was replaced with Ca2+-deficient (0 Ca2+)-ECS.  TRPM2 currents 
were abolished in the absence of extracellular Ca2+. Holding potential was -60 mV.  (B) 
Summary bar graph showing potentiation of TRPM2 currents by Fyn. Data are presented 
as mean ± SEM (control, n=9; Fyn, n=10). Statistical analysis: unpaired Student’s t-test, 
*P < 0.05. (Dr. Jillian Belrose, unpublished). 
 
A.    Control           Fyn   
B. 
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Figure S2: Fyn(39-57) attenuates TRPM2 currents in cultured hippocampal 
neurons. 
In cultured hippocampal neurons (21-28 days in vitro), repeated applications of NMDA 
(0.1 mM; 1/60 s) in the absence of exogenous ADPR caused TRPM2 current activation 
and a resultant increase in holding current over 25 minutes (Fyn CTL).  Moreover, 
intracellular application of Fyn(39-57) (25 ng/mL; in patch pipette) attenuated this 
TRPM2-mediated increase in holding current for 60 minutes (Fyn I). (Dr. Hongbin Li, 
unpublished). 
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